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1 Zusammenfassung 
Medikationsfehler und unerwünschte Arzneimittelwirkungen (UAW) treten bei hospitali-
sierten Patienten häufig auf. Meine Dissertation sollte die Häufigkeiten von Medikationsfeh-
lern und UAW bei hospitalisierten Patienten aufzeigen und Massnahmen zu derer Reduktion 
beschreiben. 
Das Hauptziel meiner Dissertation war dem entsprechend die existierenden Daten über 
Medikationsfehler und UAW in der Literatur zu reviewen, mit einem besonderen Augenmerk 
auf Frequenz und Risikofaktoren, und Massnahmen zu derer Verhütung vorzuschlagen. Et-
was detaillierter: 
– Die Literatur zwischen 1990 und 2003 nach Studien betreffend Medikationsfehler/UAW 
bei hospitalisierten Patienten zu durchsuchen und zu reviewen 
– Design und Mithilfe bei einer grossen Studie, in der potentielle Arzneimittelinteraktionen 
bei dyslipidämischen, mit einem Statin behandelten Patienten untersucht wurden 
– Das Generieren von Richtlinien zur Dosisadaptation von Chemotherapeutika bei Patien-
ten mit Leberleiden zu erstellen. Diese Studie regte ich an, weil Anfragen aus diesem Ge-
biet in Spitalapotheken nicht selten sind und weil das Nicht-Angleichen der Dosis ein Me-
dikationsfehler ist 
In der ersten Studie analysierte ich die Originalpublikationen über Medikationsfehler 
und/oder UAW bei hospitalisierten Patienten die zwischen 1990 und 2003 veröffentlicht wur-
den. Dabei fokussierte ich auf die Häufigkeit, Risikofaktoren und Massnahmen für die Ver-
meidung solcher Fehler oder Reaktionen. Zuerst führte ich einen Search in Datenbanken 
durch (Medline, Embase), wobei ich die Ausdrücke „medication error“, „adverse drug reac-
tion“, “adverse event”, „hospital“ verwendete. Ich schaute auch Reviews an, um die aufge-
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fundenen Arbeiten zu komplettieren. Die Analyse zeigte, dass Medikationsfehler mit einer 
Häufigkeit von ungefähr 5% aller Applikationen vorkommen, allerdings mit einer hohen Vari-
abilität zwischen den 29 gefundenen Studien. Diese Variabilität ist erklärt durch die Art des 
Erfassen der Medikationsfehler (systematische Erfassung vs. Spontanmeldungen) und durch 
die Art und Weise, wie die Medikamente verabreicht werden( intravenöse Arzneistoffe haben 
die höchste Fehlerrate). Fehler ereignen sich während des gesamten Medikationsprozesses, 
wobei Applikationsfehler mehr als 50% der Fehler ausmachen. Wichtige Risikofaktoren sind 
schlechte pharmakologische Kenntnisse oder Arbeitsüberlastung des Pflegepersonals und 
der Ärzte, nicht-computerisierte Verarbeitung der Verschreibungen und das Fehlen von Klini-
schen Pharmazeuten auf den Abteilungen. UAW betrafen ca. 6% aller Patienten pro Hospita-
lisation, wobei auch hier eine grosse Variabilität zwischen den 31 gefundenen Studien be-
stand. Diese Variabilität kann erklärt werden durch Unterschiede im Erfassen der Frequenz 
der UAW und durch die verschieden Abteilungen, welche studiert wurden. Risikofaktoren wa-
ren weibliches Geschlecht, Alter > 65 Jahre, Polypharmazie und Medikationsfehler. Diese 
Befunde erlaubten mir, Massnahmen zur Reduktion von Medikationsfehlern vorzuschlagen, 
insbesondere die Verbesserung der Kenntnisse in Pharmakologie aller im Medikationspro-
zess involvierter Personen, Computerisierung des gesamten Medikationsprozesses und An-
stellung von Klinischen Pharmazeuten auf den Abteilungen. 
In einer zweiten Arbeit übernahm ich das Design und teilweise die Durchführung einer 
grossen Studie, in der wir die Prävalenz von Arzneimittelinteraktionen bei dyslipidämischen 
Patienten untersuchten, welche mit einem Statin behandelt werden. Die Medikationsprofile 
und andere klinische Daten von mit Statinen behandelten Patienten wurden von 242 Prakti-
kern in der Schweiz erhalten. Die Medikationen wurden dann elektronisch mittels eines Inter-
aktionsprogramms auf potentiell schwerwiegende Interaktionen geprüft. Insgesamt prüften 
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wir 2742 ambulante Patienten (mittleres Alter 65.1 ± 11.1 [SD] Jahre, davon 61.6% männlich) 
mit 3.2 ± 1.6 (Mittelwert±SD) Diagnosen und 4.9 ± 2.4 verschriebenen Arzneistoffen. Von 
diesen Patienten hatten 190 (6.9%) insgesamt 198 potentiell schwerwiegende Statin-
Interaktionen. Interagierende Arzneistoffe waren Fibrate oder Nikotinsäure (9.5% der Patien-
ten mit einer Statin-Interaktion), CYP3A4-Inhibitoren (70.5%), Digoxin (22.6%) oder 
Cyclosporin (1.6%). Der Anteil der Patienten mit einer Statin-Interaktion war 12.1% für Sim-
vastatin, 10.0% für Atorvastatin, 3.8% für Fluvastatin, und 0.3% für Pravastatin. Das Pro-
gramm eruierte zusätzlich 393 potentiell kritische nicht-Statin-Interaktionen bei 288 Patien-
ten. Die Studie zeigte, dass die Kombination mit CYP3A4 Inhibitoren der häufigste Grund für 
potentiell schwerwiegende Interaktionen mit Statinen ist. Da Patienten mit einer solchen In-
teraktion ein erhöhtes Risiko für Rhabdomyolyse haben, sollten die Kliniker die häufigsten 
Interaktionen mit Statinen kennen und wissen, wie diese vermieden werden können. 
 In der dritten Studie regte ich an, Dosisempfehlungen für Chemotherapeutika bei Patien-
ten mit Leberleiden auszuarbeiten, basierend auf den pharmakokinetischen Eigenschaften. 
Dosisadaptationen von Chemotherapeutika sind bei Patienten mit Leberleiden wichtig, einer-
seits weil Tumorpatienten nicht selten Hepatopathien haben und andrerseits, weil Chemothe-
rapeutika einen engen therapeutischen Bereich aufweisen. Wir klassifizierten die Chemothe-
rapeutika, welche sich ende 2003 in der Schweiz auf dem Markt befanden, nach Bioverfüg-
barkeit/hepatischer Extraktion und Ausscheidungsmuster, um Voraussagen zur Dosisadapa-
tation bei Patienten mit Leberleiden machen zu können. Diese Voraussagen wurden mit kine-
tischen Studien verglichen, welche in dieser Patientenpopulation durchgeführt worden waren. 
Von den 69 aufgefundenen Arzneistoffen hatten 52 einen dominierenden extrarenalen Meta-
bolismus oder Elimination (meistens hepatisch). Für 48 Arzneistoffe konnte die hepatische 
Extraktion aufgefunden oder berechnet werden, weshalb diese Arzneistoffe nach hepatischer 
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Extraktion klassifiziert werden konnten. Für 17 Arzneistoffe fanden sich kinetische Studien in 
der Literatur, welche meistens die Grundlage für Dosisempfehlungen bilden. Präzise Emp-
fehlungen gibt es für 13 Arzneistoffe, welche biliär eliminiert werden (z.B. Doxorubicin und 
Derivate sowie Vinca Alkaloide). Allerdings fanden sich keine Validationsstudien, in welchen 
diese Dosierungsempfehlungen mit der Kinetik und Dynamik dieser Arzneistoffe bei Patien-
ten mit eingeschränkter Leberfunktion studiert wurden. Die Studie zeigt auf, dass die Daten-
lage bei den Zytostatika gegenwärtig für einen fundierten Gebrauch dieser Arzneistoffe bei 
Patienten mit Leberleiden nicht gut genug ist. Die pharmazeutische Industrie sollte deshalb 
von den Behörden dazu verpflichtet werden, kinetische Daten für die Klassifikation von Arz-
neistoffen zu liefern (insbesondere die hepatische Extraktion neuer und kritischer alter Arz-
neistoffe) und kinetische Studien bei Patienten mit Leberleiden durchzuführen, damit quanti-
tative Angaben gemacht werden können. 
 Diese Studien zeigen deutlich auf, dass Medikationsfehler und UAW bei hospitalisierten 
Patienten häufig vorkommen. Medikationsfehler sind wichtige Risikofaktoren für vermeidbare 
UAW. Für 2 Medikationsfehler, nämlich Arzneimittelinteraktionen und fehlende Dosisadapta-
tion bei Patienten mit Leberleiden, führten wir Studien durch, welche auf ihre Prävalenz fo-
kussierten und mittels welchen wir Angaben über ihre Vermeidbarkeit machen können. Spi-
tal- und klinische Pharmazeuten nehmen bei der Detektion und Vermeidung von Medikati-
onsfehlern und UAW eine wichtige Rolle ein. 
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2 Summary 
Medication errors and adverse drug reactions are frequent in hospitalized patients. 
The principle aim of my dissertation was to review the existing data about frequency and risk 
factors of these findings and to propose measures for their reduction, focusing on the possi-
bilities of hospital pharmacists. 
In more detail, the aims were: 
– To review the literature published between 1990 and 2003 for studies reporting inci-
dences of medication errors and/or adverse drug effects in hospitals 
– To investigate the prevalence of potential drug-drug interactions in ambulatory patients 
treated with a statin 
– To propose dosage guidelines for patients with liver disease being treated with antineo-
plastic drugs. This study was initiated because questions about dose adaptation of anti-
neoplastic drugs are quite frequent in hospital pharmacies 
In the first study, I analyzed the original publications about medication errors and/or ad-
verse drug reactions in hospitalized patients published between 1990 and 2003, with a focus 
on frequency, risk factors and avoidance of problems associated with pharmacotherapy. I 
performed a database search (Medline, Embase) for original articles using the terms „medi-
cation error“, „adverse drug reaction“, “adverse event”, „hospital“ and supplemented the arti-
cles retrieved by searching review articles for additional references. The analysis revealed 
that medication errors occur with a frequency of approximately 5% of all drug applications, 
with a high variability among the 29 studies retrieved. This variability is explained by the way 
medication errors are detected (systematic screening of patients or charts vs. spontaneous 
reports) and by the way drugs were administered (intravenous drugs have the highest error 
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frequency). Errors occur along the whole medication process, with application errors account-
ing for more than 50% of them. Important risk factors are insufficient pharmacological  
knowledge and work overload of the nursing staff, non-computerized transmission of pre-
scriptions and lack of clinical pharmacists on the wards. Adverse reactions affect approxi-
mately 6% of the patients per hospitalization and show a high variability between the 31 stud-
ies retrieved. This variability can be explained by different assessment of the frequency of 
adverse drug reactions and by the wards studied. Risk factors for adverse drug reactions in-
clude female sex, age >65 years, polypharmacy and medication errors. These findings al-
lowed me to propose strategies for reducing medication errors, e.g. to improve the knowl-
edge about pharmacology of all persons involved in the medication process, computerization 
of the entire medication process and the engagement of clinical pharmacists on the wards. 
 In the second study, we performed a cross-sectional analysis of the prevalence of po-
tentially serious drug-drug interactions of ambulatory dyslipidemic patients treated with a 
statin. Data of patients with dyslipidemia treated with a statin were collected from 242 practi-
tioners from different parts of Switzerland. The medication was screened for potentially harm-
ful DDIs with statins or other drugs using an interactive electronic drug interaction program. 
We included 2742 ambulatory statin-treated patients (mean age 65.1 ± 11.1 [SD] years; 
61.6% males) with 3.2 ± 1.6 (mean±SD) diagnoses and 4.9 ± 2.4 drugs prescribed. Of those, 
190 patients (6.9%) had a total of 198 potentially harmful drug-statin interactions. Interacting 
drugs were fibrates or nicotinic acid (9.5% of patients with drug-statin interactions), CYP3A4-
inhibitors (70.5%), digoxin (22.6%) or cyclosporine (1.6%). The proportion of patients with a 
potential drug-statin interaction was 12.1% for simvastatin, 10.0% for atorvastatin, 3.8% for 
fluvastatin, and 0.3% for pravastatin. Additionally, the program identified 393 potentially criti-
cal non-statin DDIs in 288 patients. Our study showed that CYP3A4 inhibitors are the most 
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frequent cause for potential interactions with statins. As the risk for developing rhabdomyoly-
sis is increased in patients having drug-statin interactions, clinicians should be aware of the 
most frequently observed drug-statin interactions and how these interactions can be avoided. 
 In the third study, we classified the antineoplastic drugs marketed in Switzerland by the 
end of 2003 according to their hepatic extraction in order to predict their kinetic behavior in 
patients with liver disease and to give dose recommendations. Dose adaptation for liver dis-
ease is important in patients treated with antineoplastic drugs due to the high prevalence of 
impaired liver function in this population and the dose-dependent, frequently serious adverse 
effects of these drugs. We therefore classified the antineoplastic drugs marketed in Switzer-
land by the end of the year 2004 according to their bioavailability/hepatic extraction in order 
to predict their kinetic behavior in patients with decreased liver function. This prediction was 
compared with kinetic studies carried out with these drugs in patients with liver disease. Of 
the 69 drugs identified, 52 had a predominant extrarenal (in most cases hepatic) metabolism 
and/or excretion. For 48 drugs, hepatic extraction could be calculated and/or bioavailability 
was available, allowing classification according to hepatic extraction. For 17 drugs, kinetic 
studies have been reported in patients with impaired liver function, with the findings generally 
resulting in quantitative recommendations for adaptation of the dosage. In particular, recom-
mendations are precise for 13 drugs excreted by the bile (e.g. doxorubicin and derivatives, 
and vinca alkaloids). Validation studies comparing such recommendations with kinetics 
and/or dynamics of antineoplastic drugs in patients with decreased liver function have not 
been published, however. The study shows that there are currently not enough data for safe 
use of antineoplastic drugs in patients with liver disease. We concluded that pharmaceutical 
companies should be urged to provide kinetic data (especially hepatic extraction) used for 
classification of such drugs and to conduct kinetic studies for drugs with primarily hepatic me-
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tabolism in patients with impaired liver function allowing to give quantitative advise for dose 
adaptation. 
 The studies show that medication errors and adverse drug reactions are frequent in hos-
pitalized patients. Medication errors are an important risk factor for avoidable adverse drug 
reactions. For two of them, drug-drug interactions and dose adaptation in patients with liver 
disease, we performed studies focusing on the incidence and guidelines for their avoidance, 
respectively. Hospital pharmacists have an important role both in the prevention and detec-
tion of medication errors and adverse drug reactions. 
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3 Introduction 
3.1 Medication errors and adverse drug reactions 
An optimal pharmacotherapy is achieved when the right drug in the correct dosage 
and quality reaches the right patient at the right time point. In particular for the hospital phar-
macist, drug therapy should also be optimized economically and the correct disposal of drug 
waste should be assured. Despite all the efforts of hospital pharmacists, physicians, nurses 
and other health professionals involved, most drug therapies have not only the desired and 
expected beneficial effects, but are associated also with adverse reactions (1). 
All circumstances, which potentially or actually impair the optimal result of pharmaco-
therapies are called „problems associated with pharmacotherapy” or shorter “drug-related 
problems” (2), consisting mainly of medication errors and adverse drug reactions (see Table 
3.1). Medication errors are errors occurring in the medication process (prescription, storage, 
preparation, handling, application of drugs, see Table 3.2). In the majority of cases, medica-
tion errors do not lead to adverse drug reactions (3, 4), but they represent a strong risk factor 
for adverse drug reactions, which can be avoided. While medication errors are judged from 
the handling of drugs, for adverse drug reactions, the patient is in the centre. It can be ex-
pected that approximately 6% of the hospitalized patients will have at least one adverse drug 
reaction during the hospitalization (1). 
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Table 3.1 Definition of problems associated with pharmacotherapy (drug-related problems) 
 
Drug-related problems All circumstances that involve a patient’s drug treatment that 
actually, or potentially, interfere with the achievement of an 
optimal outcome (2) 
Medication errors Any error in the medication process (prescribing, dispensing, 
administering of drugs), whether there are adverse conse-
quences or not (5) 
Adverse drug reactions Any response to a drug which is noxious and unintended and 
which occurs at doses normally used in humans for prophy-
laxis, diagnosis or therapy of diseases, or for the modification 
of physiological functions (6) 
Adverse drug events Any injury related to the use of a drug, even if the causality of 
this relationship is not proven (5) 
 
 
As stated above, medication errors are errors, which occur somewhere in the medica-
tion process (see Table 3.2). Their appearance is highly depending on the motivation but also 
on the formation in pharmacology of the hospital staff involved in pharmacotherapy (physi-
cians, pharmacists, nurses and others) (2). Medication errors can be grouped according to 
their appearance in the medication process (see Table 3.3). Approximately 5% of all drug 
applications contain an error (2), with application of specific drugs such as infusions being 
affected much more often (7). 
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Table 3.2 Complexity of pharmacotherapy in hospitals 
• Drug history 
• Drug prescription 
• Logistics: Preparation of drugs in the pharmacy, transport on the wards 
• Preparation and administration of drugs on the wards 
• Monitoring and individualization of drug therapies 
– Identify drug-drug interactions and adverse effects → optimization of therapy 
– Identify non-responders → find out reasons, adapt therapy 
– Find out optimal dosage (optimization of the ration between benefice and damage) 
• Explanation of the therapy before the patient leaves the hospital 
 
 
As shown in Table 3.4, adverse drug reactions can be grouped into type A and type B 
reactions (8). Type A reactions are clearly dose-dependent and predictable, and can there-
fore be prevented in most instances. Many of them may be the result of medication errors, 
since they could be avoided by using a reduced dosage. Type B reactions are idiosyncratic, 
meaning that they are rare, cannot be predicted and are not clearly dose-dependent. There 
may be risk factors such as known drug allergies or certain family diseases. In most cases, 
however, they cannot be avoided, but their course can be influenced by early recognition and 
stopping the administration of the offending drugs. 
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Table 3.3 Most important medication errors in hospitalized patients 
1. Prescription errors 
• Wrong drug (e.g. drug not suitable for this indication)  
• Correct drug, wrong patient (e.g. ignoring contra-indications, drug-drug interactions or 
drug allergies) 
• Wrong galenic form (e.g. tablets in a patient not able to swallow) 
• Wrong dose 
2. Transcription and/or interpretation errors 
• Transcription of prescriptions (e.g. physicians - nurses) 
• Usage of abbreviations, hand-written prescriptions (e.g. illegible scripture) 
• Oral prescriptions 
3. Preparation and dispensing errors (correct prescription) 
• Calculation error, preparation error 
• Dispensing (e.g. wrong patient, wrong drug) 
4. Administration error 
• Wrong dose 
• Omitting error, additional dose 
• Wrong administration time 
• Wrong handling of drugs during application (e.g. infusions) 
• Wrong infusion rate 
 
 
Beside adverse drug reactions there are other instances which can be associated with 
harm to patients treated with drugs, for instance intoxications or consequences of non-
compliance. Since adverse drug reactions are defined as reactions occurring at doses “nor-
mally used in humans for prophylaxis, diagnosis or therapy of diseases, or for the modifica-
tion of physiological functions” (see Table 3.1), such reactions are formally not adverse drug 
reactions. The term “adverse drug events” has therefore been created, which includes reac-
tions associated with the application of a drug, even if the causality is unclear (see Table 
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3.1). Adverse drug events cover therefore adverse reactions due to overdose or omitting drug 
therapy. 
 
Table 3.4 Classification of adverse drug reactions 
1. Intrinsic toxicity (predictable or Type A) 
– Clearly dose-dependent, most often exaggeration of the pharmacological effect → pre-
dictable and most of them also preventable 
– Animal models are available 
– Examples: ethanol (fatty liver), methotrexate (liver fibrosis), ACE inhibitors or angiotensin 
receptor blockers (hyperkalemia) 
2. Idiosyncratic toxicity (unpredictable or Type B) 
– Metabolic toxicity 
• Mostly after weeks to months within the first year of treatment 
• Slow reappearance after rechallenge 
• Examples: isoniazid (hepatotoxicity), valproic acid (hepatotoxicity) 
– Allergic toxicity 
• Mostly within the first two months of treatment 
• Very rapidly (1 or 2 doses) following rechallenge 
• Often accompanied by systemic reactions, typical histological changes 
• Examples: diclofenac (hepatotoxicity), phenytoin (hypersensitivity syndrome), peni-
cillins (skin reactions, cholestatic liver injury) 
 
While it is difficult for hospital pharmacists to influence the incidence of adverse drug re-
actions, in particular considering type B reactions, they can provide an important contribution 
for the identification and reduction of medication errors (3, 9-11).  
 
3.2 Studies performed 
With my dissertation I want first to give an overview about the incidence of medication er-
rors and adverse drug reactions in University and Community Hospitals. A comprehensive 
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review and meta-analysis of US studies covering adverse drug reactions has been published 
almost 10 years ago (1); it was therefore interesting to compare the incidence in this review 
with the incidences in more recent studies. Furthermore, to the best of my knowledge, such a 
comprehensive review has so far not been published for medication errors. I therefore per-
formed a search in the existing literature between 1990 and 2003 and reviewed the original 
articles reporting incidences of medication errors and/or adverse drug reactions in hospitals. 
This study also allowed me to detect the drugs involved and the underlying risk factors. 
Knowing these risk factors, I could propose measures to reduce medication errors and/or ad-
verse drug reactions. 
Since drug-drug interactions can be considered to be medication errors and I could show 
in my first study that drug-drug interactions are an important risk factor for adverse drug reac-
tions, I was interested in conducting a study in this field. I got the possibility to collaborate in a 
large study assessing the prevalence of potential drug-drug interactions in ambulatory pa-
tients suffering from dyslipidemia and being treated with a statin. My contribution was in the 
design of the study and in judging medication profiles from patients and reporting potential 
drug-drug interactions to physicians recruiting patients for the study. The study demonstrates 
that approximately 16% of dyslipidemic patients treated with a statin have potentially severe 
drug-drug interactions, approximately 7% a drug-drug interaction involving a statin. While the 
study provides the prevalence of drug-drug interactions, it does not provide the incidence of 
adverse drug reactions resulting from such interactions. Further studies are therefore neces-
sary in this field. 
A further field of interest is the adaptation of the dosage of antineoplastic drugs in pa-
tients with liver disease. Antineoplastic drugs are used frequently also in smaller hospitals 
and questions regarding dose adaptation of such drugs are not rare in hospital pharmacies. A 
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problem of antineoplastic drugs which are metabolized and/or excreted by the liver is their 
potential accumulation in patients with liver disease, possibly leading to type A adverse reac-
tions. Lack of dose adaptation in this situation can therefore also be considered to be a medi-
cation error, nicely fitting in my field of interest and in the scope of my dissertation. I therefore 
decided to review all the antineoplastic agents on the market in Switzerland by the end of the 
year 2003 and to tabulate them according to their metabolism (in particular according to their 
hepatic extraction) and excretion (in particular biliary excretion). These parameters allow 
dose adaptation for such drugs in patients with liver cirrhosis and/or cholestasis, as described 
in section 6. The study allowed also a comparison of the predicted adaptations with the im-
pairment of metabolism of such drugs in patients with liver disease. The study reveals that 
reliable data exist only for a minority of these drugs. The drug authorities should systemati-
cally demand dose adaptation studies in patients with liver disease, in particular for drugs 
with a small therapeutic range. 
 
 
3.3 References 
1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospital-
ized patients: a meta-analysis of prospective studies. Jama 1998;279:1200-1205. 
2. van den Bemt PM, Egberts TC, de Jong-van den Berg LT, Brouwers JR. Drug-related 
problems in hospitalised patients. Drug Saf 2000;22:321-333. 
3. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, 
and medication errors in United States hospitals. Pharmacotherapy 2002;22:134-147. 
4. Calabrese AD, Erstad BL, Brandl K, Barletta JF, Kane SL, Sherman DS. Medication 
administration errors in adult patients in the ICU. Intensive Care Med 2001;27:1592-1598. 
5. Leape LL. Preventing adverse drug events. Am J Health Syst Pharm 1995;52:379-
382. 
6. ASHP guidelines on adverse drug reaction monitoring and reporting. American Society 
of Hospital Pharmacy. Am J Health Syst Pharm 1995;52:417-419. 
 20 
7. Taxis K, Barber N. Ethnographic study of incidence and severity of intravenous drug 
errors. Bmj 2003;326:684. 
8. Krähenbühl A, Krähenbühl S. Unerwünschte Arzneimittelwirkungen. In: Biollaz J, ed. 
Grundlagen der Arzneimitteltherapie. Basel: Documed AG, 2001. 
9. Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events 
in hospitalized adults. J Gen Intern Med 1993;8:289-294. 
10. Cox PM, Jr., D'Amato S, Tillotson DJ. Reducing medication errors. Am J Med Qual 
2001;16:81-86. 
11. Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, Bates DW. 
Pharmacist participation on physician rounds and adverse drug events in the intensive care 
unit. Jama 1999;282:267-270. 
 21 
 
 
 
 
 
 
 
 
 
 
4 Drug related problems in hospitals – a review of the recent li-
terature 
 
 
 
 
 
 
Anita Krähenbühl-Melcher1, Raymond Schlienger2, Jürgen Drewe2, Stephan Krähenbühl2 
 
 
 
 
 
 
1Hospital Pharmacy, Regionalspital Emmental, Burgdorf and 2Division of Clinical Pharma-
cology & Toxicology, University Hospital, Basel, Switzerland 
 22 
4.1 Summary 
Background: Problems associated with pharmacotherapy (in particular medication errors and 
adverse drug reactions) are frequent and are associated with increased costs. 
Aims: To analyze the original publications about medication errors and/or adverse drug reac-
tions in hospitalized patients published between 1990 and 2003, focusing on frequency, risk 
factors and avoidance of problems associated with pharmacotherapy. 
Methods: Data base search (Medline, Embase) for original articles using the terms „medicati-
on error“, „adverse drug reaction“, “adverse event”, „hospital“. The original articles retrieved 
were supplemented by searching review articles for additional references. 
Results: Medication errors occur with a frequency of approximately 5% of all drug applicati-
ons, with a high variability among the 29 studies retrieved. This variability is explained by the 
way medication errors are detected (systematic screening of patients or charts vs. spontane-
ous reports) and by the way drugs were administered (intravenous drugs have the highest 
error frequency). Errors occur along the whole medication process, with application errors 
accounting for more than 50%. Important risk factors are insufficient pharmacological know-
ledge and work overload of the nursing staff, non-computerized transmission of prescriptions 
and lack of clinical pharmacists on the wards. Adverse drug reactions affect approximately 
6% of the patients per hospitalization and show a high variability between the 31 studies 
retrieved. This variability can be explained by different assessment of the frequency of adver-
se drug reactions and by the wards studied. Risk factors for adverse drug reactions include 
female sex, age >65 years, polypharmacy and medication errors. 
Conclusions: Since medication errors are strong risk factors for avoidable adverse drug reac-
tions, strategies have to be put in place for their reduction. Such strategies include a good 
pharmacological formation of all persons involved in the medication process (nurses, phar-
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macists and physicians), computerization of the entire medication process and the engage-
ment of clinical pharmacists on the wards. 
 
4.2 Introduction 
Drugs not only have beneficial effects but can also be associated with adverse reacti-
ons. During the last decade, several studies have been published highlighting the significan-
ce of adverse drug reactions in hospitalized patients in terms of frequency (1-4), consequen-
ces for the affected patients (5-7) and costs for the hospitals (8-10). Adverse drug reactions 
can be regarded as the top of a pyramid, which contains all problems associated with drug 
therapy or “drug related problems”. Drug related problems include all problems, which can 
potentially affect the success of pharmacotherapy in a given patient, in particular medication 
errors, adverse drug events and adverse drug reactions (7). A more precise definition of the-
se terms is given in Table 4.1 and a graphical illustration in Figure 4.1. 
Medication errors can occur along the whole medication process and represent risk 
factors for adverse drug reactions (5, 11, 12). As shown in Table 4.2, the medication process 
starts with the prescription of a drug, the prescription has to be transmitted usually to a nurse 
and also into the pharmacy for delivery of the prescribed drugs. Nurses usually prepare the 
drugs on the ward, and distribute and administer them to the patients. The steps, which have 
been reported to be particularly afflicted with errors are drug prescription and drug administ-
ration (7). 
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Table 4.1 Definition of problems associated with pharmacotherapy (drug-related problems) 
Drug-related problems All circumstances that involve a patient’s drug treatment 
that actually, or potentially, interfere with the achieve-
ment of an optimal outcome (7) 
Medication errors Any error in the medication process (prescribing, dispen-
sing, administering of drugs), whether there are adverse 
consequences or not (13) 
Adverse drug reactions Any response to a drug which is noxious and unintended 
and which occurs at doses normally used in humans for 
prophylaxis, diagnosis or therapy of diseases, or for the 
modification of physiological functions (14) 
Adverse drug events Any injury related to the use of a drug, even if the causa-
lity of this relationship is not proven (13) 
 
Since medication errors can be a pre-stage of adverse drug reactions, knowledge of 
their origin and of possible risk factors involved is important for their avoidance. One of the 
aims of the current investigation was therefore to assess these risk factors in order to be able 
to propose measures for avoiding medication errors in community and university hospitals. 
Special emphasis was put on the role of the clinical pharmacists in this setting, since several 
publications have emphasized the importance of a direct supervision of the medication pro-
cess by pharmacists (15-17). 
We therefore performed a search of the literature published between 1990 and 2003 in 
order to retrieve the relevant original publications reporting the frequency of medication errors 
and/or adverse drug reactions in hospitalized patients. From these data, we extracted the 
frequency and the risk factors of these drug-related problems, in order to be able to propose 
suitable measures for their reduction. 
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Table 4.2 Most important medication errors in hospitalized patients 
 
1. Prescription errors 
• Wrong drug (e.g. drug not suitable for this indication)  
• Correct drug, wrong patient (e.g. ignoring contra-indications, drug-drug interactions or 
drug allergies) 
• Wrong galenic form (e.g. tablets in a patient not able to swallow) 
• Wrong dose 
 
2. Transcription and/or interpretation errors 
• Transcription of prescriptions (e.g. physicians - nurses) 
• Usage of abbreviations, hand-written prescriptions (e.g. illegible scripture) 
• Oral prescriptions 
 
3. Preparation and dispension errors (correct prescription) 
• Calculation error, preparation error 
• Dispension (e.g. wrong patient, wrong drug) 
 
4. Administration error 
• Wrong dose 
• Omittion error, additional dose 
• Wrong administration time 
• Wrong handling of drugs during application (e.g. infusions) 
• Wrong infusion rate 
 
4.3 Methods 
 We performed a computer search in Medline and Embase using the search terms 
„medication error“ or “adverse drug reaction” or “adverse drug event” in combination with 
“hospital” and collected the relevant articles published between 1990 and 2003. The articles 
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retrieved were searched manually and those reporting original data concerning the frequency 
of medication errors, adverse drug events and/or adverse drug reactions in hospitalized pati-
ents were included in the review. Furthermore, review articles covering these subjects were 
also searched and used for completing the references reporting original data. As already dis-
cussed in a preceding publication (4), studies reporting adverse drug events can pose prob-
lems in their classification. Unlike adverse drug reactions, adverse drug events also include 
medication errors such as overdosing (see definitions in Table 4.1). Such studies were there-
fore reviewed very carefully and were mostly classified under medication errors. If the avai-
lable data allowed the calculation of the frequency of adverse drug reactions, they could also 
be classified under adverse drug reactions or under both medication errors and adverse drug 
reactions. Using these methods, we detected 29 articles reporting frequencies of medication 
errors and 31 articles reporting frequencies of adverse drug reactions in hospitalized patients. 
 The frequencies reported were analyzed according to the type of hospital (University 
vs. non-University hospitals), the type of ward the data were collected, and the detection sys-
tem used to collect the data. If not indicated otherwise, data are presented as medians and 
range, since the frequencies of the medication errors and adverse drug reactions showed no 
normal distribution. Statistical analysis was performed using the non-parametric Mann-
Whitney U test when 2 groups were compared. When more than two groups were compared, 
the Kruskal-Wallis analysis of ranks was used, followed by the Mann-Whitney U test with 
Bonferroni correction to localize significant differences. A p<0.05 was considered to be sta-
tistically significant. 
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Adverse drug events
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Figure 4.1 Problems associated with pharmacotherapy 
Problems associated with pharmacotherapy (drug-related problems) can be illustrated with 
the intersections of three circles representing medication errors, adverse drug events and 
adverse drug reactions. Medication errors include every mistake in the medication process 
(prescribing, dispensing, administering of drugs). Only a minority of the medication errors are 
resulting in an adverse drug reaction or an adverse drug event. Adverse drug events repre-
sent any injury related to the use of a drug, even if the causality of this relationship is not pro-
ven. Adverse drug reactions are noxious responses to a drug which are unintended and 
which occur at normally used doses of this drug. Adverse drug reactions are either predic-
table (and therefore mostly avoidable, type A reactions), or unpredictable (idiosyncratic or ty-
pe B reactions). 
 
4.4 Results 
 A total of 60 articles were detected, 29 articles reporting medication errors (Table 4.4) 
and 31 articles reporting adverse effects of drugs (Table 4.5). Studies, which were not carried 
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out in hospitals or which did not indicate the frequency of medication errors or adverse drug 
reactions were not included. 
 
4.4.1 Medication errors 
 Considering the medication errors, it has to be taken into account that the methods 
used to measure errors and the way to express error rates differ among studies, rendering 
the results difficult to compare. As shown in Figure 4.2, medication errors are most often de-
termined as the percentage of errors per administrations. Alternatively, the percentages of 
the patient days with at least one error or of patients with at least one error during their hospi-
talization are used. The reported error rates were 5.4 errors per 100 administrations (range 
0.038-49, n=22), 1.1 errors per 100 patient days (range 0.35-12, n=6) or 5.8 errors per 100 
patients per hospitalization (range 0.15-24, n=9). A close inspection of the data in Figure 4.2 
reveals that the variability in the error frequencies is large, even within the groups with the 
same units for error frequencies. The reasons for this high variability are primarily different 
drugs the patients studied were treated with, but also different methods used to determine 
the error rate. Looking at the errors given as a percentage of administrations in Figure 4.2, 
the two error rates exceeding the 95% percentile originate from studies where a comprehen-
sive monitoring (daily monitoring of patients for a series of predefined events) of the administ-
ration of mainly intravenous fluids was performed (18, 19). On the other hand, the error rate 
below the 5% percentile in the same Figure originates from a large multicentre trial where 
spontaneous reports were collected (20). 
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Figure 4.2 Frequency of medication errors 
The frequency of medication errors occur is in about 5% of all drug applications, 1.1 er-
rors per 100 patient days or 5.8 errors per 100 patients per hospitalization. The variability in 
the error frequencies is large, irrespectively how the error rate is determined. The most im-
portant reasons for this high variability are different drugs the patients are treated with and 
different methods used to determine the error rate (see Figure 4.3). In the errors given as a 
percentage of administrations, the two error rates exceeding the 95% percentile originate 
from studies where a comprehensive monitoring of the administration of mainly intravenous 
fluids was performed (18, 19). The error rate below the 5% percentile originates from a large 
multicentre trial where spontaneous reports were collected (20). Data are represented as box 
plots (25th to 75th percentile) containing both the median (solid line) and the average (dotted 
line). T-bars indicate the 5th and 95th percentile. 
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The influence of the method used for error detection was investigated further for all stu-
dies reporting the error rate per administration (Figure 4.3). Although the variability remains 
large, comprehensive monitoring (median 6.8, range 2.4-49 errors per 100 administrations, 
n=13) revealed significantly more errors than spontaneous reporting (2.3, range 0.038-3.3, 
n=3). 
 In studies reporting the error rate per administration, the type of hospital (University vs. 
non-University) was not associated with a difference in the error rate. The median error rate 
was 4.2 (range 0.038 – 26.9, n=17) in University hospitals and 5.95 (range 3.5 – 19%, n=4) in 
non-University hospitals. Considering the wards, which were investigated, the numbers are 
too small for meaningful statistical comparisons. A comparison of the medians, which are in 
the range of 3 – 6.6 errors per 100 administrations (with large ranges), did not reveal sub-
stantial differences, however. As stated already above, the ward per se appears to less im-
portant than the type of drugs which are administered on this ward. 
 Drug classes which are prone to errors include in particular antibiotics, cardiovascular 
drugs, oral anticoagulants, theophyllin and antineoplastic drugs (compare Table 4.4). Errors 
occur at all stages of the medication process, most often at the administration stage (median 
57.5% of all errors, range 28-90%, n=22 studies), unauthorized administration of drugs (25%, 
range 4-28%, n=3 studies), drug prescription (18.5%, range 6-78%, n=8 studies), transcripti-
on (15%, range 11-21%, n=4 studies) and drug preparation (13.5%, range 7-23%, n=4 stu-
dies). Considering drug administration, frequent errors are omission of a dose (range 36-
74%), wrong application time (14-25%), wrong dose (12-56%) and wrong administration rate 
(5.5-40%). 
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Figure 4.3 Dependence of the medication error frequency on the mode of detection 
The influence of the method used for error detection was investigated further for all studies 
reporting the error rate per administration (first plot in Figure 4.2). Comprehensive monitoring 
(daily monitoring of patients for a series of predefined events) reveals significantly more er-
rors than spontaneous reporting (median 6.8 vs 2.3 errors per 100 administrations, p<0.05). 
Data are represented as box plots (25th to 75th percentile) containing both the median (solid 
line) and the average (dotted line). T-bars indicate the 5th and 95th percentile. 
 
The most important risk factors for medication errors include lack of information about drugs 
or about the patients to be treated, errors in the patient charts and/or in the documentation of 
the nurses and lacking or decentralized pharmacy services. Recommendations for reducing 
medication errors include the installation of a decentralized clinical pharmacy service (the cli-
nical pharmacists must be present on the wards) (5), an improved education in pharmacothe-
rapy for the first year residents (21), an electronic ordering and patient survey system (1) and 
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the installation of a “no-blame” error reporting system (22). Regarding the intravenous admi-
nistration of drugs, preparation of complex solutions in the hospital pharmacy and replace-
ment of bolus applications by short infusions are recommended (19). 
 
4.4.2 Adverse drug reactions 
 Similar to the studies reporting medication errors, most of the studies about adverse 
drug reactions were carried out in University Hospitals, mainly on wards of internal medicine. 
Only 3 reports originate from Community Hospitals, two from wards of internal medicine and 
one from a geriatric ward (Table 4.5). Due to the small number of the reports from Communi-
ty Hospitals, a statistical comparison with University Hospitals is not meaningful. In one of 
these studies, a retrospective review of patient charts revealed a frequency of 0.59% of pati-
ents with an adverse drug reaction during hospitalization (23). The two other studies carried 
out in community hospitals reported higher frequencies, namely 23.1% by chart review of pa-
tients on a medical ward (16) and 60.7% by chart review on a geriatric ward (24). 
 In contrast to the medication errors, the frequency of adverse drug reactions is given 
with the same units for all of the studies included, namely as the percentage of patients suffe-
ring from an adverse drug reaction per hospitalization. While these units are helpful for a 
comparison of the frequencies between studies, they disregard the fact that an individual pa-
tient can suffer from more than one adverse drug reaction during one hospitalization. The 
true frequency of adverse drug reactions may therefore be higher than reported in Table 4.5 
and Figure 4.4. 
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Figure 4.4 Dependence of the incidence of adverse drug reactions on the mode of detection 
The overall frequency of the adverse drug reactions is 6.0% (median) of the patients during 
one hospitalization. Similar to the medication errors (Figure 2), the variability between studies 
is large, possibly originating from different methods used to determine adverse drug reactions 
and from different wards studied. The frequency of adverse drug reactions detected by spon-
taneous reporting (median 2.2% of patients) is significantly lower than that obtained by com-
prehensive monitoring (12.8% of patients) or by chart review (13% of patients). Data are re-
presented as box plots (25th to 75th percentile) containing both the median (solid line) and the 
average (dotted line). T-bars indicate the 5th and 95th percentile. 
 
The overall frequency of the adverse drug reactions is 6.0% (median) of the patients 
during one hospitalization (range 0.2 – 60.7%). The large range suggests differences bet-
ween the studies, possibly regarding the methods used to determine adverse drug reactions 
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and also regarding the wards the patients were studied. The frequency of adverse drug reac-
tions was either determined by spontaneous reporting (physicians, pharmacists, nurses), by 
intensive monitoring of the patients (regular review of the chart and visit of the patients and 
visit of the patients by physicians, pharmacists and/or study nurses), by systematic chart re-
view (either during or after hospitalization), by computerized monitoring of predefined adver-
se drug events and/or by interviewing the patient at the end of the stay in the hospital. As 
shown in Figure 4.4, the frequency of adverse drug reactions detected by spontaneous repor-
ting (median 2.2% of patients, range 0.2-7%, n=15 studies), is significantly lower than obtai-
ned by comprehensive monitoring (12.8% of patients, 1.3-27%, n=10 studies) or by chart re-
view (13% of patients, 0.59-60.7%, n=12 studies). Since there was only one study using pati-
ent interviews (25), this technique was not included in the calculations in Figure 4.4. Compu-
terized monitoring of adverse drug events is a different approach to assess adverse drug 
reactions as compared to the other techniques. An array of pathological laboratory values 
and clinical events are predefined and “hits” are created, when the corresponding signs or 
values of a patient fall into the predefined pathological range (24, 26-28). Since not every hit 
corresponds to a true adverse drug reaction, such studies were only included, when the fre-
quency of adverse drug reactions was also assessed by one of the conventional methods. 
The studies using computerized monitoring show, however, that this technique has a sensiti-
vity of 57% (range 47.5 – 73%, n=4) to detect adverse drug reactions. Since computerized 
monitoring appears to be less time consuming than comprehensive monitoring or systematic 
review of patient charts, it may be a technique deserving more attention in the future. 
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Figure 4.5 Dependence of the incidence of adverse drug reactions on the wards the patients 
were studied. 
The box plots represent all studies performed with patients on wards of internal medicine 
(n=21 studies). In comparison, in all 5 studies on geriatric wards (circles), the frequency of 
the adverse drug reactions was higher than the 95% interval obtained for studies on wards of 
internal medicine, irrespective of the method used. In contrast, the frequency of adverse drug 
reactions for patients studied in intensive care units (n=1 study), psychiatry (n=2), neurology 
(n=1) or cardiology (n=1) was similar to patients on wards of internal medicine. Data are re-
presented as box plots (25th to 75th percentile) containing both the median (solid line) and the 
average (dotted line). T-bars indicate the 5th and 95th percentile. 
 
In addition to the technique how the data are collected, the frequency of adverse drug 
reactions detected appears also to depend from the ward the study was performed. As 
shown in Table 4.5, 5 studies were conducted on geriatric wards and in all 5 studies, the fre-
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quency of the adverse drug reactions was higher than the 95% interval obtained for studies 
performed on wards of internal medicine (n=21 studies), irrespectively how the adverse reac-
tions were determined. The frequency of adverse reactions in patients on medical wards was 
3.1% of patients (0.2-23.1%, n=21 studies) versus 27% of patients on geriatric wards (7.1-
60.7%, n=5 studies), the difference reaching statistical significance (p<0.05). On the other 
hand, the frequency of adverse drug reactions for patients studies in intensive care units (n=1 
study), psychiatry (n=2), neurology (n=1) or cardiology (n=1) was similar to patients on wards 
of internal medicine, but the number of studies and of patients investigated is small. 
In 3% of the patients (range 0.51 -7%, n=5), an adverse drug reaction was the reason 
for the hospitalization, and 2.45% of the patients (range 0.14-3.5%, n=4) of the patients died 
because of an adverse drug reaction. 62.5% (range 42.3 – 100%, n=8) of the adverse drug 
reactions detected were type A reactions and thus potentially preventable. In 15% (range 4.8 
– 31%, n=5) of the adverse drug reactions, the reason was a drug-drug interaction. 
 Risk factors for the occurrence of adverse drug reactions were reported in 6 studies 
(2, 16, 29-32). The most important risk factors appear to be polypharmacy (3/6 studies), fe-
male sex (3/6), drugs with a narrow therapeutic range (2/6), drug-drug interactions (2/6), and 
renal elimination of drugs (1/6), age >65 years (1/6) or a history of allergies (1/6). In patients 
having an adverse drug reaction, the stay in the intensive care unit was prolonged for 3.4 
days or the hospitalization for 3.8 days (range 1.2 – 8.5 days, n=5), leading to an increase in 
costs per hospitalization. 
 
4.5 Discussion 
Our study demonstrates that medication errors occur in about 5% of all drug applicati-
ons and adverse drug reactions in about 6% of all patients per hospitalization. Since, at least 
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on medical wards, patients are usually treated with 5-10 drugs per day and stay for approxi-
mately 8 days in the hospital (2), they may have about 50 drug applications per hospitalizati-
on, suggesting that most patients will be affected by one or more medication errors. On the 
other hand, approximately 6% of the patients have an adverse drug reaction, indicating that 
only a minority of medication errors will lead to a clinical manifestation. In agreement with 
these considerations, it has been estimated in clinical studies that approximately 3-5% of all 
medication errors result in adverse drug reactions (5, 33, 34). The importance of medication 
errors is therefore primarily given by the facts that they represent risk factors for adverse drug 
reactions and that they are avoidable. 
About 59% (median) of the adverse drug reactions are judged to be preventable (ran-
ge 50-87%, n=7 studies) (3, 30, 35-39) and can therefore be considered to be primarily the 
result of medication errors. Looking at the risk factors for adverse drug reactions (polyphar-
macy, female sex, drugs with a narrow therapeutic range, drug-drug interactions, renal elimi-
nation of drugs, age >65 years, ignored allergies; see result section) it becomes evident that 
drug-drug interactions, failure of dose adaptation in patients with impaired renal function and 
failure to recognize previous drug allergies are in fact medication errors. 
Drug-drug interactions can therefore be considered as medication errors, representing 
risk factors for adverse drug reactions. In the studies analyzed, drug-drug interactions were 
estimated to account for a median of 5% (range 4.8-17%) of all adverse drug reactions (23, 
24, 40, 41), affecting approximately 0.3% of the patients per hospitalization. Since the preva-
lence of potentially severe drug-drug interactions is in the range of 60% in hospitalized pati-
ents (42), only a small fraction (<1%) of the potential drug-drug interactions appear to cause 
adverse drug reactions. The fraction of the patients with a potentially serious drug-drug inter-
action being affected by an adverse drug reaction depends on the drugs involved. While the 
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incidence of severe hyperkalemia (>6mmol/L) in patients treated with an ACE inhibitor or an 
angiotensin receptor blocker and low dose (25 mg/day) spironolactone has been reported to 
be in the range of 6% per year (43), rhabdomyolysis in patients treated with atorvastatin or 
simvastatin and an inhibitor of CYP3A4 occurs with an at least 50 times lower incidence (44). 
Medication errors occur along the entire medication process, from drug prescription to 
administration (7). Drug administration was found to be affected most often, followed by u-
nauthorized drug administration, prescription, transcription and drug preparation. Regarding 
drug administration, in particular intravenously administered drugs are prone to errors (18, 
19). To increase drug safety, intravenous bolus administrations should be replaced by short 
infusions and complex infusions should be prepared in the local pharmacy (19). While u-
nauthorized drug administration and transcription errors can be reduced by organizational 
measures and/or computerized prescription (45), reduction of prescription errors is more 
complex. Important risk factors for prescription errors include high workload, prescribing for a 
foreign patient, communication deficits within the team and lack of knowledge in pharma-
cotherapy (46). Real-time electronic prescription aids may be helpful to reduce such errors 
(1, 17, 34, 47). 
A list of possibilities to reduce medication errors is given in Table 4.3. Several studies 
have shown that improved pharmacological knowledge of physicians and nurses is an effi-
cient measure for error reduction (48-51). Considering nurses, a single short instruction is not 
sufficient (52), repetitive instructions are necessary. Furthermore, as discussed above, presc-
ription and transcription errors can be reduced by computerizing the medication process, e.g. 
by introduction of electronic patient charts and electronic alert systems (1, 17, 34, 47). Re-
garding prescription, real time information containing important drug data such as dosage 
(with suggestions for dose adaptation in the case of impaired renal or hepatic function), ad-
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verse drug reactions, contra-indications and drug-drug interactions customized for individual 
patients would be most helpful. As discussed above, complex intravenous administrations 
should be prepared in the pharmacy and not on the ward and short infusions should be used 
instead of boli (19). A couple of studies have shown that clinical pharmacists on the ward can 
help to reduce medication errors (5, 17, 21, 34, 53, 54). Taking into account the costs caused 
by adverse drug reactions (8, 10, 26, 55), employment of clinical pharmacists on medical and 
surgical wards may be cost effective for hospitals. 
Furthermore, medication errors should be discussed in an open, no-blame, non-
punishing atmosphere (22). Voluntary critical incidence reporting systems including regular 
discussions with all professional groups involved appear to be most suitable for this purpose 
(56). 
Our data show that a median of 6% of the patients will suffer from an adverse drug re-
action during their hospitalization. This figure is close to the incidence of 6.7% reported in a 
meta-analysis from publications between 1966 and 1996 (4), suggesting that the incidence of 
adverse drug reactions has remained constant over the last 3 to 4 decades. In approximately 
60% of the patients, the adverse drug reactions were considered to be potentially preven-
table, thus to originate from a medication error. In comparison, in a recent report from a 
Swiss University Hospital where patients on a medical ward are monitored comprehensively 
for adverse drug events, the fraction of adverse events due to medication errors was much 
lower, namely in the range of 6% (57). Possible explanations for this discrepancy include dif-
ferences in the definition of preventability of adverse drug events and differences in the 
wards studied. Risk factors for adverse drug reactions reported were polypharmacy, female 
sex, administration of  
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Table 4.3 Prevention of problems associated with pharmacotherapy 
1. Medication errors 
• Improved pharmacological education of health professionals (nurses, pharmacists, physi-
cians) 
• “Computerization” of the medication process 
– Prescribing aids 
– Improved transcription 
– Improved monitoring of patients 
• Clinical pharmacists on the ward 
– Identification of reporting of medication errors/adverse events 
– Control for drug-drug interactions 
– Dose adaptation in patients with impaired renal and/or liver function 
– Monitoring of complex therapies 
• Critical incident reporting systems 
2. Adverse drug reactions 
Type A (dose-dependent, predictable) 
• Limit polypharmacy as much as possible 
• Consequent dose adaptation according to function of the elimination organs 
• Avoidance of drug-drug interactions and of other medication errors 
Type B (not predictable, idiosyncratic) 
• Difficult to avoid, since not predictable 
• Avoid risk factors 
– Prior reactions to drugs 
– Family history of drug reactions 
• Limit damage in case of an adverse drug event: Consider to stop all drugs which are not 
life-saving 
drugs with a narrow therapeutic range, drug-drug interactions, renal elimination of drugs, age 
> 65 years and ignoring drug allergies. Polypharmacy is a frequent finding particularly in a-
ged, polymorbid patients, but is often difficult to avoid (58, 59). Polypharmacy is associated 
with an increased risk of adverse drug reactions not only because of the addition of the risk of 
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the individual drugs, but also because of possible drug-drug interactions (44). Polypharmacy 
may therefore explain at least partially the higher incidence of adverse reactions observed in 
geriatric as compared to internal medicine wards (see Table 4.5). As discussed above, drug-
drug interactions, missed dose adaptation in patients with impaired renal function and igno-
red drug allergies are medication errors, which may lead to adverse reactions, depending on 
the drugs involved and on the individual patient. 
As shown in Table 4.3, the preventive strategies for adverse drug reactions differ bet-
ween type A (predictable and preventable) and type B (not predictable and in most cases not 
preventable) adverse drug reactions. Considering type A reactions, they can be targeted by 
reducing polypharmacy and medication errors. For type B reactions, prevention is much more 
difficult, since these reactions are not predictable. Preventive strategies include avoiding 
known risk factors and limiting damage to the individual, once an adverse reaction has occur-
red. 
In conclusion, medication errors and adverse drug reactions are frequent findings in 
hospitalized patients, potentially leading to increased duration of the stay in the hospital or 
even to fatalities and increased costs for the hospitals. Risk factors are known and should 
guide the preventive measures. 
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Table 4.4 Studies reporting the frequency of medication errors in hospitalized patients 
 
Type of hospital; 
ward 
Duration, appli-
cations 
Detection methods Error frequency  Most frequent medication errors Remarks Refe-
rence 
University hospi-
tal; all units 
12 months; 
279'818 applica-
tions per month 
Spontaneous re-
porting 
0.038% of all ap-
plications (107 
errors per month) 
Errors: 37% omission, 28% u-
nauthorized drugs, 14.8% wrong 
time, 11.6% wrong dose, 5.5% 
wrong rate 
Frequency increased 
with duration of study 
(suggesting learning 
effect) 
(20) 
University hospi-
tal; all units 
37 days; 2967 
patient days 
Systematic review 
of patient charts 
and spontaneous 
reporting 
10 per 1000 pd 
(33 in coronary 
care units, 13 on 
medical wards) 
Drugs: antibiotics 25%, cardiac 
drugs 15%, anticoagulants 10% 
72% of the errors per-
formed by physicians, 
10% by pharmacists, 
8% by nurses 
(60) 
University hospi-
tal; internal me-
dicine 
294 discharge 
medications 
Actual verification 
of prescriptions 
(clinical pharma-
cists) 
5.8% (17 errors in 
294 prescriptions) 
Errors: 41% wrong dosage. 11 
errors were potentially harmful 
Risk factors: 24% lacking infor-
mation 
Most errors by first year 
residents. Clinical 
pharmacists detected 2 
thirds of errors 
(21) 
Community 
hospital; outpa-
tient clinics 
Year 1: 691 pre-
scriptions (base-
line) 
Year 2: 921 pre-
scriptions (post-
intervention) 
Actual verification 
of prescriptions 
(clinical pharma-
cists); comparison 
pre-/post-
intervention 
Baseline: 14.4% 
of prescriptions 
Post-intervention: 
6% of prescripti-
ons 
Intervention was feedback to 
baseline errors 
Prescribing errors can 
be reduced by teaching 
(48) 
University hospi-
tal; internal me-
dicine including 
ICU 
8 months; 1484 
patient days 
Systematic review 
of patient charts 
(research nurses) 
315 adverse oc-
currences (0.2 
per pd), among 
them 178 medica-
tion errors (0.12 
per pd) 
Errors: 74% missed dose Medication errors most 
frequent. Nurses admi-
nistration records are 
best source for detecti-
on 
(61) 
University hospi-
tals; surgical 
and medical u-
nits including 
ICUs 
6 months; 
21'412 patient 
days (pd) 
Systematic review 
of patient charts 
(research nurses) 
and spontaneous 
reporting 
20.6 errors per 
1000 pd. ADEs: 
11.5 per 1000 pd. 
Medical ICUs 
19.4, surgical I-
CUs 10.5,  
medical units 
Errors: 49% prescription, 11% 
transcription, 14% dispensing, 
26% administration stage. 
Drugs: classes most affected 
were analgesics 30%, antibiotics 
24% and sedatives 8%. 
28% of ADEs preventable, 12% 
Many ADEs are serious 
and/or preventable. 
Computerized ordering 
could prevent most 
ADEs. 
(1) 
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Type of hospital; 
ward 
Duration, appli-
cations 
Detection methods Error frequency  Most frequent medication errors Remarks Refe-
rence 
10.6, surgical u-
nits 8.9. Potential 
ADEs: 9.1. per 
1000 pd 
(17%) of the ADEs (potential 
ADEs) life threatening 
USA: University 
hospital; general 
medicine 
UK: University 
hospital; general 
medicine 
USA: 1 month; 
919 applications 
UK: 2 months; 
2756 applicati-
ons 
USA: actual verifi-
cation (study nur-
se) 
UK: retrospective 
review of prescrip-
tion (study nurse) 
USA: 6.9% 
UK: 3.0% 
Errors: USA: incorrect dose 
30%, unordered drug 25%. UK: 
omission 58%, incorrect dose 
14%. 
Risk factors: USA: Incorrect se-
lection or preparation by nurse 
52%, unclear prescription 37%, 
incorrect drug supplied by 
pharmacy 6%. UK: Incorrect se-
lection or preparation 40%, drug 
unavailable on unit 39%, unclear 
prescription 13% 
English system (clinical 
pharmacists on ward) 
better than USA system 
(single dose unit) 
(53) 
University hospi-
tal; all units inc-
luding ICUs 
9 years; 
3’903‘433 presc-
riptions 
Systematic review 
of all prescriptions 
(clinical pharma-
cists) 
11’186 errors; 
6.52 errors per 
1000 patient days 
(2.87 per 1000 
orders). 1.22 se-
rious errors/1000 
pd. 
Errors: overdose 37%, underdo-
se 19%, allergy 14%, duplication 
6%, wrong drug 4%  
Drugs: xanthines 20%, antibio-
tics 12%, cough 7% 
Error frequency increa-
ses with complexitiy of 
therapies and new 
drugs  
(12)) 
University hospi-
tal; all units 
1 year; 525'750 
prescriptions 
Systematic review 
of all prescriptions 
(clinical pharma-
cists). Only clini-
cally relevant er-
rors. 
2103 errors; 3.99 
errors per 1000 
orders. 696 could 
potentially cause 
ADR.  
Errors: Overdose 42%, under-
dose 16%, allergy 13%, dosage 
form 12%, wrong drug 5% 
Drugs: xanthines 20.6/1000 or-
ders, antibiotics 13.6, cardio-
vascular 5.01, hormones 3.84 
Risk factors: limited knowledge 
of drug therapy (30%) or of pati-
ent factors (29%) 
Education in pharma-
cotherapy must be im-
proved 
(49) 
District hospital; 
geriatric unit 
14 days; 2335 
orders 
Systematic review 
of all patient 
5.1% of orders 
(1.5% if docu-
Error: Documentation (failures in 
nurses’ notes) 67%, dosage 
Adverse effects in a 
third of all medication 
(62) 
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Type of hospital; 
ward 
Duration, appli-
cations 
Detection methods Error frequency  Most frequent medication errors Remarks Refe-
rence 
charts (clinical 
pharmacists) 
mentation errors 
not counted) 
19%, omission 9% errors possible 
District hospital; 
all units except 
intensive care 
units 
1 month, 839 
applications. 
One month, 855 
applications af-
ter intervention 
Systematic inves-
tigation of drug 
orders and appli-
cations (study 
nurses) 
6.8% of all appli-
cations before 
and 3.5% after 
intervention 
Errors before intervention: 28% 
wrong application time, 25% 
wrong administration, 19% 
wrong prescription 
Intervention included 
teaching of personnel 
about medication er-
rors. Effectful in particu-
lar in nurses 
(50) 
University hospi-
tal; surgery 
23 days; 5515 
applications. 31 
days, 7391 ap-
plications after 
intervention 
No-blame sponta-
neous reporting 
Before interventi-
on 3.3%, after 
intervention 2.3% 
Errors: Omission 36% (28%), 
wrong documentation 21% 
(39%), wrong time 25% (19%) 
and wrong dose 1.7% (2.4%) 
before and after (parentheses) 
intervention 
No-blame self reporting 
system better than o-
ther self-reporting sys-
tems. Intervention was 
performed according to 
failure mode effects 
analysis (FMEA) 
(22) 
University hospi-
tal; all except 
obstetrical units 
6 months; 9306 
patients 
Computerized re-
gistration of 37 
predefined risk 
situations 
Risk situation 
(adverse event or 
error) in 6.4% of 
patients (true rate 
may be higher, 
only 37 events 
recorded) 
Most frequent events: risk situa-
tion for digoxin toxicity, renal 
failure due to radio contrast me-
dia, phenytoin toxicity 
28% of all events and 
42% of life threatening 
events may be preven-
ted. Computerized alert 
system recommended 
(47) 
University hospi-
tal; intensive 
care unit for 
children 
10 weeks; 275 
applications 
Actual verification 
of administration 
(study nurse) 
26.9% of admi-
nistrations 
Errors: Wrong time 32%, wrong 
administration technique 32%, 
wrong dose preparation 23% 
High frequency becau-
se of intensive care u-
nit. Reduction by phar-
maceutical monitoring 
(18) 
University hospi-
tal; intensive 
care unit (gene-
ral, cardiologi-
cal, recovery 
room) 
13 months; 385 
patients in gene-
ral ICU, 552 in 
cardiological 
ICU, 8429 in 
recovery room 
Spontaneous re-
ports 
Total 0.93% (87 
per 9366 pati-
ents). In the ge-
neral ICU 13.2% 
(51 per 385 pati-
ents) 
Errors: wrong dose or preparati-
on, wrong medication/infusion, 
wrong administration.  
37% of errors had con-
sequences for the pati-
ent. Most of the errors 
reported from ICU. True 
frequency is higher 
(63) 
University hospi-
tal; intensive 
care unit (car-
75 patients be-
fore and after 
intervention, 75 
Systematic review 
of all prescriptions 
(clinical pharma-
Preventable A-
DE’s (errors) dec-
reased from 10.4 
Errors: incomplete orders, 
wrong dose, wrong frequency, 
duplicate therapy 
Clinical pharmacists 
can prevent two thirds 
of the ADEs during 
(54) 
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Type of hospital; 
ward 
Duration, appli-
cations 
Detection methods Error frequency  Most frequent medication errors Remarks Refe-
rence 
diology) from control unit cists) before to 3.5 after 
intervention (per 
1000 patient 
days). Control 
group 10.9 and 
12.4 (per 1000 
patient days) 
prescription 
UK: University 
hospital; general 
medicine (Clini-
cal pharmacist) 
Germany 1: U-
niversity; surge-
ry (traditional 
distribution sys-
tem) 
Germany 2: U-
niversity; inter-
nal medicine 
(Unit dose sys-
tem) 
UK: 842 solid 
oral doses 
Germany 1: 973 
solid oral doses 
Germany 2: 
1318 solid oral 
doses 
 
Comprehensive 
monitoring 
 
UK 8% 
Ger 1: 5.1% 
Ger 2: 2.4% 
Errors: Omission, wrong dose, 
wrong drug, transcription, orde-
ring administration 
Lower medication error 
rate associated with the 
unit dose system 
(64) 
University hospi-
tal; medical in-
tensive care unit 
2009 admi-
nistrations 
Comprehensive 
monitoring 
6.6% (132 errors) Errors: Dose 31%, wrong rate 
22%, wrong preparation techni-
que 18%, incompatibility 14% 
26 errors potentially life-
threatening 
Risk factors: medication track, 
insufficient staff training 
 (65) 
University hospi-
tal; pediatrics 
3312 medication 
orders (669 pa-
tient-days) 
Daily review of the 
medical records 
23.7% (784 errors 
in 3312 prescrip-
tions) 
Errors: “intercepted” errors 98% 
(prescribing, dispensing, transc-
ription), 2% administration errors 
In pediatrics, the most 
common medication 
errors are dosing errors 
(66) 
University hospi-
tal; HIV-infected 
patients 
1618 admissi-
ons 
Medication orders 
were reviewed 
(pharmacist) prior 
5.8% (108 presc-
ribing errors in 
1618 admissions 
Errors: under-dosing 48%, over-
dosing 34%, drug-drug interacti-
ons 5.6%. 
The high frequency of 
prescribing errors is 
related to the complex 
(67) 
 52 
Type of hospital; 
ward 
Duration, appli-
cations 
Detection methods Error frequency  Most frequent medication errors Remarks Refe-
rence 
to dispensing affecting 94 pati-
ents) 
HIV treatment regimens 
University hospi-
tal; pediatrics 
112’536 admis-
sions or 335’835 
patient-days 
Retrospective re-
view of medication 
errors 
0.15% of admis-
sions (195 er-
rors): 
Medical wards 
59%, surgical 
wards 13%, ICUs 
27% 
Errors: incorrect iv infusion 
15.8%, dose 14.8%, extra dose 
13.8%, dose omitted 12.3% 
Drugs: Antibiotics 44%, parente-
ral nutrition 16.5%, anticancer 
drugs 10.1, morphine 4.6% 
 (68) 
1116 Hospitals 
(university and 
community); ge-
neral medicine 
8'500'000 pati-
ents 
Spontaneous re-
ports 
5.07% errors. Mo-
re errors in com-
munity than uni-
versity hospitals 
Risk factors: decentralized or 
lacking clinical pharmacists, 
high pharmacist workload 
Medication errors with sym-
ptoms: 0.25% of patients 
Errors rate may be re-
duced by installing a 
decentralized clinical 
pharmacy service 
(5) 
5 University 
hospitals; inten-
sive care units 
5744 observati-
ons in 851 pati-
ents 
Monitoring of cer-
tain medications 
3.3% of all admi-
nistrations (187 
errors) 
Errors: wrong infusion rate 
40.1%. 
Drugs: cardiovascular 32.6%, 
sedative/analgesics 25.7%. 
 
20 errors did not reach 
patient, 159 reached 
patient but did not re-
sult in harm, 5 required 
monitoring, 2 required 
intervention. None of 
the errors resulted in 
death 
(33) 
2 University 
hospitals; ICU 
10’778 admi-
nistrations, 1120 
patients 
Comprehensive 
monitoring (physi-
cian) 
5.7% of admi-
nistrations (616 
errors) 
Errors: physician ordering 74%, 
dosing 28%, route of administra-
tion 18%, transcription 14% 
Administration: intravenous 
55%, oral 21% 
Drugs: antibiotics 20%, analge-
sics 16%, electrolytes 26% 
115 errors resulting in 
potential ADR (1.1%), 
26 ADR (0.24%). 
Computerized orde-
ring/clinical pharmacist 
can prevent >90% of 
errors 
(34) 
36 hospitals and 
nursing facilities 
3216 applicati-
ons 
Comprehensive 
monitoring (re-
search pharma-
cist) 
19% of applicati-
ons (605 errors in 
3216 doses) 
Errors: Wrong time 43%, dose 
omitted 30%, wrong dose 17%, 
unauthorized drug 4%. 
No difference between universi-
ty and community hospitals 
7% potentially harmful 
errors 
(69) 
 53 
Type of hospital; 
ward 
Duration, appli-
cations 
Detection methods Error frequency  Most frequent medication errors Remarks Refe-
rence 
2 University 
hospitals; pedi-
atrics  
10778 medicati-
on orders for 
1020 patients 
Chart review (phy-
sicians) 
5.7% of all orders 
(616 errors), 120 
potentially harm-
ful medication 
errors 
Errors: drug ordering 77.8%, 
dosing 28.4%, route 17.7%, 
transcription 15.9%, administra-
tion 12.8% 
Recommendations: e-
lectronic ordering, clini-
cal pharmacists, impro-
ved communication  
(17) 
University hospi-
tal; cardiology 
24538 patients 
over 4.5 years 
Comprehensive 
monitoring (clinical 
pharmacist) 
24% of patients 
(4768 errors). 
Due to physicians 
in 63%, pharma-
cist in 26%, nur-
sing in 5% 
Errors: wrong drug 36%, wrong 
dose 35.3%, dose omitted 
10.2% 
Drugs: cardiovascular 41.2%, 
antibiotics 14.9%, GI-tract 9.5% 
Recommendations: Up-
to-date information for 
physicians and nurses, 
better education for 
new interns 
(51) 
1. University 
hospital; general 
medicine 
2. Non teaching 
hospital; general 
medicine 
430 intravenous 
administrations 
(106 patients) 
Comprehensive 
monitoring (clinical 
pharmacists, phy-
sician, nurses) 
49% of all admi-
nistrations (212 of 
430 applications), 
3 rated as serious 
Errors: wrong preparation 7%, 
wrong administration 36%, both 
wrong 6%.  
Risk factors: Multiple preparati-
on steps, bolus injection 
Recommendations: 
central preparation of 
complex products, short 
infusion instead of bo-
lus 
(19) 
2 University 
hospitals; medi-
cal and surgical 
units. 
12 weeks in e-
very hospital. 
5792 (medicati-
on nurses: trai-
ning of 2 days) 
and 3661 (gene-
ral nurses) ap-
plications 
Comprehensive 
monitoring (trained 
nurses or pharma-
cy technicians) 
15.4% of all ad-
ministrations. Ge-
neral nurses 
14.9%, medicati-
on nurses 15.7%. 
Medical units 
13.2%, surgical 
units 11.7% (only 
hospital A) 
Errors: Administration technique 
42%, preparation 9%, omitted 
drug 6%, wrong dosage 5%, 
wrong route 4% 
Outcome: no adverse drug reac-
tions observed 
Simple education of 
nurses to become me-
dication nurses has no 
benefit. Education must 
be more detailed and 
deserves more studies 
(52) 
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Table 4.5 Studies reporting the frequency of adverse drug reactions in hospitalized patients 
 
Type of hospital; 
specialty 
Patients, du-
ration of study 
Detection method ADR frequency Most frequent ADRs 
or organs affected 
(in% of ADRs) 
Remarks Refe-
rence 
University hospi-
tal; internal me-
dicine 
160 patients; 
1 month 
Comprehensive 
assessment (clini-
cal pharmacist) vs. 
spontaneous re-
porting 
8.8% (14/160) vs. 
2.5% (4/160). „True 
rate“ (combination) 
15/160. 
Drugs: Antibiotics 
40%. Organs: GI-
tract 33%, kidney 
20%, liver 13%, CNS 
13% 
Intensive screening (clinical 
pharmacist) is better than 
spontaneous reporting. Inten-
sive screening detects 93%, 
spontaneous reporting 27% of 
ADRs. 
(70) 
51 hospitals in 
the state of New 
York; general 
medicine 
30'195 patient 
charts 
Retrospective re-
view of charts 
0.59% (178/30'195); 
18% due to negligen-
ce, 14% resulting in 
permanent disability. 
Only serious ADRs 
recorded. 
Drugs: Antibiotics 
16%, chemotherapy 
16%, anticoagulants 
11%. Organs: Bone 
marrow 16%, blee-
ding 15%, CNS 15%, 
cutaneous 14%. 
Drug-drug interactions ac-
counted for 4.8% of ADRs 
(23) 
University hospi-
tal; geriatrics 
416 patients, 
10 weeks 
Comprehensive 
assessment (phy-
sicians) 
27% of patients Drugs: Diuretics 55%, 
beta-blockers 8%, 
antidepressants 
4.5%, opiates 4%, 
NSAIDs 4% 
50% of ADRs were due to 
drugs which considered to be 
contra-indicated or unneces-
sary. 240 potential drug-drug 
interactions in 150 patients, 
5% caused ADR. 
(40) 
University hospi-
tal; geriatrics 
(ambulatory and 
hospitalized pati-
ents) 
463 patients Retrospective re-
view of charts 
21% of patients ACE-inhibitors 17%, 
diuretics 14%, anti-
depressants 10%, 
NSAIDs 10% 
31% of patients have potential 
drug-drug interaction. Risk 
factors for ADRs: drug-drug 
interactions, drugs requiring 
therapeutic drug monitoring 
(20) 
University hospi-
tal; medical 
wards 
30 057 pati-
ents, 1 year 
Spontaneous re-
porting vs. chart 
review (predefined 
events) 
Spontaneous repor-
ting 1.7%, chart re-
view 3.1% of patients 
Spontaneous repor-
ting: antibiotics 77%, 
digoxin 7%, analge-
sics 3%. Chart re-
view: antibiotics 32%, 
analgesics 13%, psy-
Chart review of predefined 
events better than spontane-
ous reporting 
(71)) 
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Type of hospital; 
specialty 
Patients, du-
ration of study 
Detection method ADR frequency Most frequent ADRs 
or organs affected 
(in% of ADRs) 
Remarks Refe-
rence 
chotropics 9% 
Community hos-
pital; medical 
ward 
1024 patients; 
4 months 
Chart review 23.1% of patients 
(2.6% of all drug ex-
posures) 
Drugs: Furosemide 
12%, diltiazem 3.6%, 
enalapril 3%. Organs: 
metabo-
lic/hematologic 33%, 
GI-tract 18%, geni-
tourinary 12% 
Risk factors: age > 65 years, 
females > males, number of 
„drug exposures“ 
(16) 
University hospi-
tal; internal me-
dicine 
440 patients; 
2 months 
Spontaneous re-
porting vs. chart 
review 
Chart: 9.4% (males) 
and 11.2% (females), 
total 10% (56 ADRs 
in 44 patients). Spon-
taneous: 15 patients 
(3.4%) with 17 ADRs 
Hypokalemia (diure-
tics), hyperkalemia 
(ACE inhibitors, po-
tassium), hyponatre-
mia (diuretics) 
122 ADRs in 98 patients were 
present at admission (22.3% 
of patients). Spontaneous re-
porting is less efficient than 
chart review. Only definite and 
probable ADRs. 
(72) 
University hospi-
tal; internal me-
dicine 
12229; 2 
years 
Spontaneous re-
ports 
2.2% of patients ADRs: hypersensitivi-
ty 29.3%, drug intoxi-
cations 19.9%, cardi-
ovascular 15.9%. 
Drugs: antibiotics 
29%, cardiovascular 
agents 21%, anticon-
vulsants 10%) and 
psychotropics 9%.  
Preventive interventions: de-
velopment of a clinical phar-
macist-run anticoagulation 
clinic, drug utilization evaluati-
on of phenytoin, dosing algo-
rithm for theophylline. 
(73) 
Community hos-
pital, internal 
medicine 
10587 pati-
ents; 7 
months 
Spontaneous re-
ports verified by 
clinical pharmacist 
1.9% of patients 
(19% were conside-
red to be preven-
table) 
Drugs (non-
preventable): antibio-
tics 42% (58), cardio-
vascular 16% (6), 
analgesic 13% (10). 
Organs: Cutaneous 
50%(38), bleeding 
13% (0.6), cardiac 
13% (0.6) 
Preventable: 50% type A, 
50% allergic. Risk factors: al-
lergy not recognized, oral an-
ticoagulants, drugs with the-
rapeutic drug monitoring, re-
nally eliminated drugs 
(30) 
University hospi- 105 patients; Systematic review 37% with certain or Drugs (during stay): Risk factors: stay in hospital, (31)) 
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Type of hospital; 
specialty 
Patients, du-
ration of study 
Detection method ADR frequency Most frequent ADRs 
or organs affected 
(in% of ADRs) 
Remarks Refe-
rence 
tal; geriatrics 3 months of charts probable ADR during 
admission and stay 
(during stay age-
dependent and hig-
her) 
Diuretics 32%, laxati-
ves 21%, antibiotics 
21% 
but not number of drugs or 
number of diagnoses 
University hospi-
tal; internal me-
dicine 
24500 vs 
25530 pati-
ents; both 
phases 1 year 
Spontaneous re-
ports vs. compre-
hensive assess-
ment (pharma-
cists) 
Spontaneous: 0.4% 
of patients. Compre-
hensive: 1.3% of pa-
tients 
Organs: Cutaneous 
41%, respiratory 
14%, neurologic 
14%, hematologic 
12%  
Comprehensive assessment: 
Standardization of detection 
system, active participation of 
hospital pharmacists. Drug-
drug interactions 5%, medica-
tion errors 7% of all ADRs. 
(41) 
University hospi-
tal; psychiatry 
3809 patients; 
5 years 
Spontaneous re-
ports 
3% of patients Drugs: cyamemazine 
24%, carbamazepine 
24%, fluvoxamine 
20%, fluoxetine 20% 
Risk factors: females > males, 
age no risk factor. Drug-drug 
interactions in 15% 
(32) 
University hospi-
tal; psychiatry 
50 patients; 1 
year 
Systematic review 
of charts 
16% (8 patients) with 
at least 1 ADR 
Neuroleptics are in-
volved in 9 of twelve 
ADRs 
Of 12 ADRs: 2 certain, 8 pro-
bable, 2 possible 
(74) 
University hospi-
tal; internal me-
dicine 
666 patients, 
9 months 
Spontaneous re-
ports 
2.7% of patients (cer-
tain, probable, pos-
sible ADRs) 
No information 3.5% of patients had ADR as 
a reason for hospitalization. 
51% of ADRs were preven-
table. 51% type A, 49% type B 
reactions. 81% severe or mo-
derate. 
(35) 
University hospi-
tal, internal me-
dicine 
20695 pati-
ents, 3 years 
Spontaneous re-
porting 
6.9 % of all patients Drugs: NSAIDs, anti-
coagulants, digoxin 
Organs: GI-bleeding, 
impaired renal functi-
on 
80% of ADRs type A, 20% 
type B. Drug-drug interactions 
in 20%. Most of the ADRs we-
re reported by nurses and 
pharmacists. Only 6.3% of the 
ADRs to be reported were ac-
tually reported to authorities 
(36) 
University hospi-
tal; internal me-
91574 pati-
ents, 4 years 
Spontaneous re-
porting. Control 
2.4% of patients Drugs: morphine, di-
goxin, meperidine, 
ADRs are associated with pro-
longation of hospitalization 
(6) 
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Type of hospital; 
specialty 
Patients, du-
ration of study 
Detection method ADR frequency Most frequent ADRs 
or organs affected 
(in% of ADRs) 
Remarks Refe-
rence 
dicine group. oxycodone (1.74 days), increased mortali-
ty (1.05 vs. 3.5%) and cost 
(2014 $ per patient) 
University hospi-
tal; internal me-
dicine 
153 patients; 
2 months 
Retrospective 
chart review vs. 
computerized mo-
nitoring 
16% vs. 24% (only 
certain and probable) 
Organs: renal im-
pairment 31%, hepa-
tic impairment 19%, 
eosinophilia 19%. 
Computerized system (labora-
tory data) in combination with 
clinical signs detects 65% of 
ADRs 
(28) 
University hospi-
tal; internal me-
dicine 
329 patients; 
6 months 
Comprehensive 
monitoring (physi-
cian). Control 
group. 
6.6% of patients du-
ring hospitalization 
Organs: allergy 14%, 
hypotension 12%, 
dehydration 12%, 
sleepiness, falls 12%, 
GI disorders 12% 
At admission, 3% of patients 
had ADR. 66% of ADRs are 
type A. Excess hospital stay is 
8.5 day in patients with ADR. 
(3) 
University hospi-
tal; internal me-
dicine 
370 patients; 
9 months 
Comprehensive 
monitoring (phar-
macist) 
16.8% of patients 
(definite, probable, 
possible) 
Organs: hematologi-
cal 51%, GI-tract 
22%, kidney 7%, liver 
3% 
7% of patients were admitted 
due to ADR. 59% of the ADRs 
type A. Mortality of patients 
with ADR 2.9% 
(37) 
University hospi-
tal; internal me-
dicine 
1959 patients 
(941 test, 
1018 control 
units); 2 years 
Spontaneous re-
porting vs. com-
prehensive moni-
toring (pharmacist) 
2.1% of patients 
(spontaneous) vs. 
14.6% (comprehensi-
ve) (definite, pro-
bable, possible) 
Organs: GI-tract 
27.2%, CNS 16.1%, 
cardiovascular 
14.3%, metabolic 
12.1%, blood 7.1%, 
skin 5.4% 
After stopping comprehensive 
monitoring, ADR reporting ra-
tes go rapidly back to pre-
intervention levels 
(75) 
University hospi-
tal; gastro-
intestinal 
98 patients; 
17 months 
Retrospective 
chart review vs. 
computerized mo-
nitoring 
17.9% of patients 
(definite and pro-
bable) 
Organs: Liver 44%, 
kidney 15%, electro-
lytes 15%, blood 
11%, glucose 11% 
Computerized monitoring yiel-
ded 82 events, 27 were con-
sidered definite/probable, 30 
possible ADRs. 
(26) 
University hospi-
tal; internal me-
dicine 
379 patients, 
7 months 
Chart review vs. 
computer based 
vs. spontaneous 
12% of patients (pro-
bable and possible); 
6% were severe. 
Computer-based 
34/46 (4.4%) and 
spontaneous repor-
ting 17/46 (2.2%) 
Drugs: antibiotics 
28%, cardiovascular 
11%, antiretrovirals 
11%, neuroleptics 9% 
Computer-based monitoring 
detects 73% of ADRs. 
(26) 
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Type of hospital; 
specialty 
Patients, du-
ration of study 
Detection method ADR frequency Most frequent ADRs 
or organs affected 
(in% of ADRs) 
Remarks Refe-
rence 
University hospi-
tal; internal me-
dicine 
4331 patients, 
3 years 
Comprehensive 
monitoring 
11% clinically rele-
vant ADRs (in 16% 
clinical event, in 31% 
abnormal laboratory 
value). Mortality 
0.14%. 
Drugs: chemotherapy 
30.7, iloprost 14.3%, 
cyclosporin A 4.6%, 
antibiotics 2.8%, anti-
virals 2.6% 
Organs: GI-tract 131, 
blood 112, skin 93, 
CNS 61, cardiovas-
cular 27 
RF: female sex, polypharmacy 
(not age). Prolongation of 
hospitalization by ADR for 1.2 
days. 
(2) 
University hospi-
tal; general me-
dicine 
9311 patients, 
5 months 
Actual review of 
charts (pharma-
cists, nurses, phy-
sicians). Control 
group 
2.1% of patients  Drugs: antibiotics 
17.1%, cardiovascu-
lar 16.5%, NSAIDs 
14.6%, psychotropics 
5.5% 
Organs: GI-tract 
24%, skin 19%, Im-
munology 15%, CNS 
13% 
Definite 8%, probable 69%, 
possible 21%. Severe 17%, 
2% lethal. Patients with ADRs 
have 3.8 days more in hospi-
tal, costing approximately 
5000$. 
(76) 
University hospi-
tal; internal me-
dicine 
444 patients, 
4 months 
Comprehensive 
monitoring (physi-
cians, pharmacist) 
4.7% of patients du-
ring hospitalization. In 
7% reason for hospi-
talization, in 21.4% 
ADR present at 
hospitalization. 
Drugs: Antibiotics 
38%, immunoglobulin 
15%, topical steroids 
15%. Organs: neuro-
logic 31%, skin 23%, 
GI-tract 15%, liver 
15% 
42.3% type A reactions, ap-
proximately 50% preventable. 
Risk factors: polypharmacy 
during hospitalization. 7.5% of 
hospital bed days due to 
ADRs. 
(38) 
University hospi-
tal; cardiology 
16916 pati-
ents, 18 
months 
Stimulated spon-
taneous reporting. 
Control group. 
1.69% of patients du-
ring hospitalization. In 
0.51% reason for 
hospitalization (likely, 
possible, doubtful). 
Drugs: Contrast me-
dia 20%, antibiotics 
14%, anticoagulants 
13%, diuretics 6%. 
Organs: cutaneous 
24%, cardiovascular 
21%, metabolic 12%, 
coagulation 10%, 
Frequency is age-dependent. 
18 (5%) ADRs life-
threatening, 18 (5%) lethal. 
Patients with ADRs stay 4 
days longer in hospital. 
(9) 
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Type of hospital; 
specialty 
Patients, du-
ration of study 
Detection method ADR frequency Most frequent ADRs 
or organs affected 
(in% of ADRs) 
Remarks Refe-
rence 
neurologic 10% 
University hospi-
tal; general me-
dicine 
21365 pati-
ents; 4 
months 
Spontaneous re-
porting 
0.2% of patients Drugs: anticoagulants 
18%, cardiovascular 
16%, CNS drugs 
12%, NSAIDs 6%. 
Organs: Coagulation 
18%, neurologic 
16%, cardiovascular 
12%, GI-tract 10% 
None of the serious or new 
ADRs was reported to the au-
thorities. 
(77) 
University hospi-
tal; neurology 
332 patients; 
2 months cli-
nical monito-
ring. 600 pati-
ents; 3 
months com-
puterized mo-
nitoring 
Clinical monitoring 
vs. computerized 
monitoring 
Clinical monitoring: 
15.4% of patients. 
Computerized moni-
toring: 18.5% of pati-
ents (sensitivity 
45%). 2.7% of pati-
ents with ADR at 
entry. 
Organs (severe 
ADRs): CNS 53%, 
hematology 14%, re-
spiratory 12%, GI-
tract 7%, cardiovas-
cular 7% 
After combination of both me-
thods, sensitivity of clinical 
monitoring is 72%, computeri-
zed monitoring 45%. 
(27) 
University hospi-
tal; surgical ICU 
401 patients; 
2 years and 7 
months 
Actual reviewing 
of charts. Control 
group. 
9.2% of patients 
(1.1% of drug expo-
sures) 
Drugs: morphine 
33%, meperidine 
23%, metamizole 
18% 
Organs: vomiting 
18%, hypotension 
15%, nausea 15%, 
itchiness 10% 
87% of ADRs are type A reac-
tions. Patients with ADR were 
3.4 days longer on ICU. 
(39) 
Community hos-
pital; geriatrics 
163 patients; 
5 months 
Actual reviewing 
of charts (pharma-
cist) vs. compute-
rized monitoring 
60.7% of patients by 
chart reviewing. 
Computerized moni-
toring detected 
47.5% of ADRs. 
Drugs: cardiovascular 
26%, affecting blood 
22%, psychotropics 
20%. Organs: GI-
tract 26%, liver 18%, 
metabolic 17%, car-
diovascular 9%, cu-
taneous 7% 
Drug-drug interactions cause 
17% of ADRs (2198 signals, 
1.2% of signals with ADR). 
Idiosyncrasy 21%, intolerance 
7%, „adverse effect“ 40%, 
„secondary pharmacological 
effect“ 9%, allergy 5% 
(24) 
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Type of hospital; 
specialty 
Patients, du-
ration of study 
Detection method ADR frequency Most frequent ADRs 
or organs affected 
(in% of ADRs) 
Remarks Refe-
rence 
University hospi-
tal; geriatrics 
168 patients; 
8 months 
Spontaneous re-
porting vs. inter-
view with patients 
(pharmacist) 
7.1% of patients 
(spontaneous) or 
41% patients by in-
terview. 
Drugs (spontaneous): 
cardiovascular 33%, 
CNS 33%, antibiotics 
8%. Drugs (inter-
view): cardiovascular 
31%, respiratory 
22%, CNS 16% 
All ADRs were type A reacti-
ons. For ADRs by interview 
72% probable and 28% pos-
sible. 
(25) 
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5.1 Abstract 
Background: Drug-drug interactions (DDIs) are a well known risk factor for adverse 
drug reactions. Statins are a cornerstone in the treatment of dyslipidemic patients, and 
patients with dyslipidemia are concomitantly treated with a variety of additional drugs. 
Since DDIs are associated with adverse reaction, we performed a cross-sectional study 
to assess the prevalence of potentially critical drug-drug and drug-statin interactions in 
an outpatient adult population with dyslipidemia. 
Methods: Data of patients with dyslipidemia treated with a statin were collected from 
242 practitioners from different parts of Switzerland. The medication was screened for 
potentially harmful DDIs with statins or other drugs using an interactive electronic drug 
interaction program. 
Results: We included 2742 ambulatory statin-treated patients (mean age 65.1 ± 11.1 
[SD] years; 61.6% males) with 3.2 ± 1.6 (mean±SD) diagnoses and 4.9 ± 2.4 drugs 
prescribed. Of those, 190 patients (6.9%) had a total of 198 potentially harmful drug-
statin interactions. Interacting drugs were fibrates or nicotinic acid (9.5% of patients with 
drug-statin interactions), CYP3A4-inhibitors (70.5%), digoxin (22.6%) or cyclosporine 
(1.6%). The proportion of patients with a potential drug-statin interaction was 12.1% for 
simva-statin, 10.0% for atorvastatin, 3.8% for fluvastatin, and 0.3% for pravastatin. Addi-
tionally, the program identified 393 potentially critical non-statin DDIs in 288 patients. 
Conclusions: CYP3A4 inhibitors are the most frequent cause for potential interactions 
with statins. As the risk for developing rhabdomyolysis is increased in patients having 
drug-statin interactions, clinicians should be aware of the most frequently observed 
drug-statin interactions and how these interactions can be avoided. 
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5.2 Introduction 
Drug-drug interactions (DDIs) are an important cause for adverse drug reactions. It 
has been estimated that approximately 5% of prescribing errors (1) or of adverse drug 
reactions (2) are due to DDIs in hospitalized patients. In a recent investigation, 2.3% to 
7.8% of adverse effects in association with the use of co-trimoxazole, digoxin or ACE-
inhibitors were found to be due to interactions with specific concomitant drugs (3). Po-
lypharmacy, which is associated with the number of diagnoses in a given patient (4), 
has been identified as a major risk factor for DDIs. Additionally, the way a drug is meta-
bolized and/or excreted is a major determinant of potential DDIs (5). Regarding drug 
metabolism, drugs undergoing degradation by cytochrome P450 isoenzymes (CYPs) 
carry a particularly high risk for DDIs, because of the large number of drugs inhibiting or 
inducing CYPs (5, 6). Additionally, clinically relevant DDIs can arise on the level of 
transport proteins responsible for renal and/or biliary excretion of endogenous and exo-
genous substances. Examples are interactions involving P-glycoprotein (P-gp), e.g. in-
teractions between statins and digoxin (7) or clarithromycin and digoxin (8, 9). 
Interactions with statins can lead to rhabdomyolysis, a severe adverse reaction 
which may be fatal (10, 11). A recent study in Ireland estimated that approximately 30% 
of all users of statins have concomitant drugs prescribed which can inhibit statin meta-
bolism, potentially leading to rhabdomyolysis (12). It is known that the interaction poten-
tial differs between individual statins (13, 14). Atorvastatin, lovastatin and simvastatin 
are all biotransformed by CYP3A4, the most abundant CYP isozyme, which metabolizes 
most drugs undergoing CYP-associated biotransformation (6, 15). Accordingly, the risk 
for interactions is highest for drugs metabolized by CYP 3A4, particularly, if no other 
CYP isozymes are involved in their biotransformation. Fluvastatin is primarily metaboli-
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zed by CYP2C9, an isozyme which is less abundant than CYP3A4 making the 
drug less prone to DDIs (16, 17). Pravastatin is more hydrophilic due to a hydroxyl 
group allowing conjugation of the drug without previous phase I biotransformation (13, 
14). Accordingly, the risk for interactions with pravastatin is estimated to be lower than 
for statins undergoing CYP-dependent metabolism (16, 17). Because data on the preva-
lence and risk factors for potential DDIs in ambulatory patients are rare and interactions 
in patients treated with statins can be associated with severe adverse effects (10, 11, 
18), we identified potential DDIs in ambulatory, hyperlipidemic patients treated with a 
statin to assess (1) the prevalence of potential DDIs in association with statin therapy, 
(2) to assess the prevalence of other potential DDIs not involving statins, and (3) to i-
dentify risk factors for potential DDIs in this population. 
 
5.3 Methods 
5.3.1 Subjects, study design and data collection 
Between February to April 2002, practitioners from different parts of Switzerland 
were recruited to participate in the ‘Swiss Analysis Focused on the Evaluation of Poten-
tial Drug Interactions’ (SAFE). The participating practitioners screened all patients at-
tending their practice during five consecutive days and completed a data sheet of each 
dyslipidemic patient with statin therapy. The form included data on year of birth, sex, the 
statin prescribed, indication for the statin, main diagnoses and all concomitantly prescri-
bed drugs. Diagnoses were coded according to the International Statistical Classificati-
on of Disease and Related Health Problems (ICD-10) and drugs according to the WHO 
Drug Dictionary (Version 01-3, third quart 2001). All patient data were recorded in an 
electronic database and all drug profiles were screened by the online version of Drug-
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Reax Interactive Drug Interactions (Micromedex™ Healthcare Series Vol. 111-
115 / Exp 03-12/2002) (19), a drug interaction program that was used in several previ-
ous studies (20-22). This program has proven to be more sensitive to predict potential 
DDIs than expert physicians (22). 
 
5.3.2 Database and semiautomatic screening by Drug-Reax 
Drug-Reax, an interactive electronic drug interaction program with a filter for se-
verity rating (major, moderate, minor) and providing referenced information on the clini-
cal picture caused by a given DDI, was used for screening potential DDIs (19). For this 
project, a specific software for data management and entry was developed. The soft-
ware allowed coding of diagnoses according to ICD-10 and of drugs according to the 
WHO Drug Dictionary. Phenprocoumon and acenocoumarol, the two oral anticoagu-
lants used in Switzerland, were coded as warfarin, because they are not listed in Drug-
Reax. After the entry of all drugs of one single patient, the software prepared data re-
cords for all possible drug-drug combinations for the patient (number of drug 
pairs/patient = (number of drugs x (number of drugs - 1) / 2)). By using the browser ob-
ject of MS-Access, a semiautomatic search was started in Drug-Reax and the result 
was pasted into the database. A systematic parsing procedure analyzed the search re-
sults, which consequently had to be assigned to the correct drug-drug pair. With this 
procedure over 30,000 drug-drug pairs were screened. Drug combinations with the po-
tential of relevant interactions for either compound were separated for further evaluati-
on. 
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5.3.3 Evaluation of clinical relevance of potential drug interactions 
Drug-statin interactions 
Each patient and medication profile with a possible drug-statin interaction detected 
by Drug-Reax, was evaluated by a pharmacist and a clinical pharmacologist for clinical 
relevance. A drug-statin combination was considered critical or potentially harmful and 
therefore clinically relevant if 1) the respective statin was combined with a known inhibi-
tor of its metabolism and/or transport; 2) there was at least one published case report 
describing this interaction, or 3) the potential adverse effect could have had a serious 
outcome. Serious outcome was defined as described by the ICH guidelines for clinical 
safety data management of adverse drug reactions (23). In case of disagreement, the 
specific interaction was discussed until consensus between both assessors was rea-
ched. 
 
Non-statin DDIs 
Each drug profile with a possible non-statin DDI of ‘major severity’ according to 
Drug-Reax or with a DDI not recognized by Drug-Reax, but by manual screening u-
sing standard literature (24, 25), an additional online drug interaction database 
(www.pharmavista.ch) and/or Medline, was evaluated by a pharmacist and a clinical 
pharmacologist. DDIs were considered as potentially harmful (and therefore clinically 
relevant), if the potential adverse effect of this interaction could have had a serious out-
come. Serious outcome was defined as described by the ICH guidelines for clinical sa-
fety data management of adverse drug reactions (23). A DDI of “major severity” accor-
ding to Drug-Reax was considered as not being clinically relevant, if the interaction did 
not correspond to the actual clinical situation (e.g. first-dose hypotension of ACE-
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inhibitors in patients having long-term treatment with ACE-inhibitors and diuretics), 
or if one of the potentially interacting drugs was administered topically (e.g. treatment 
with topical ketoconazole in a patient treated with a CYP3A4 substrate). In case of di-
sagreement between the two assessors, the specific interaction was discussed until 
consensus was reached. 
 
5.3.4 Statistical analysis 
Possible differences of age, number of diagnoses and number of drugs between 
the groups of patients treated with the different statins were tested by one-way ANOVA. 
Categorical variables were tested by Pearson χ2. The 5%-significance level (α-criterion) 
was adjusted for multiple testing according to Bonferroni-Holm (26). 
Potential drug-statin and non-statin DDIs were analyzed by logistic regression 
analyses using a backward elimination procedure with Wald statistics and likelihood-
ratio statistics. The occurrence of potential drug-statin or non-statin DDIs was used as 
the response variable. Explanatory variables put in the two models of drug-statin and 
non-statin DDIs included the dichotomous variables male sex, French speaking part of 
Switzerland, Italian speaking part of Switzerland, diagnosis of hypertension, diabetes, 
coronary heart disease, cardiac failure, arrhythmias, depression/psychiatric disorders, 
cerebrovascular diseases, rheumatic diseases/diseases of the musculoskeletal system, 
gout/hyperuricemia, epilepsia, and other diagnoses (see Table 5.1) The continuous va-
riables included in the model were age (years), number of diagnoses, number of presc-
ribed drugs, and number of prescribed pharmacologically active compounds. Explanato-
ry variables were included in the final model, if the p-value was < 0.1. 
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The final model of drug-statin interactions comprised the following explanato-
ry variables: Number of diagnoses, number of prescribed drugs, diagnosis of hyperten-
sion, diabetes, cardiac failure, arrhythmias, and French speaking part of Switzerland. 
The influence of the prescribed statin was assessed by an indicator variable for the use 
of pravastatin (yes/no), i.e. pravastatin was tested against all other statins. The following 
parameters were put in the final non-statin DDI model as explanatory variables: Male 
sex, number of prescribed pharmacologically active compounds, diagnosis of diabetes, 
cardiac failure, arrhythmias, cerebrovascular diseases, and gout/hyperuricemia. The in-
fluence on non-statin DDIs was assessed by an indicator variable for the presence of 
potential drug-statin DDIs. Relative risk estimates are expressed as odds ratios (ORs) 
with 95% confidence intervals (95% CI). 
Statistical analyses were performed with SPSS for Windows version 10.1.4 (SPSS 
Inc., Chicago, Illinois 60606). 
 
5.4 Results 
5.4.1 Drug-statin interactions 
From February through April 2002, 242 practitioners (43.0% general practitioners, 
41.7% internists, 13.6% cardiologists and 1.7% others), from different parts of Switzer-
land recorded the medication of 2,753 dyslipidemic patients treated with a statin. Eleven 
patients were excluded from the analysis: ten patients were not prescribed a statin and 
one patient was on cerivastatin, a statin withdrawn from the market in 2000. Patients 
were recruited in the German (49.2%), French (37.9%) or Italian (12.9%) speaking part 
of Switzerland. Pravastatin was prescribed in 34.1% of all patients, atorvastatin in 
32.3%, simvastatin in 27.8%, and fluvastatin in 5.8%. Patient characteristics are sum-
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marized in Table 5.1. The 2,742 patients included had a total of 8,943 diagnoses 
(mean 3.2 ± 1.6 per patient) and were prescribed a total of 12,766 drugs (mean 4.9 ± 
2.4 drugs per patient, range 1-21). The most prevalent co-morbidities beside dyslipide-
mia were arterial hypertension, coronary heart disease, diabetes mellitus, cerebrovas-
cular diseases, psychiatric illnesses, arrhythmias and cardiac failure. In comparison to 
the other statins, patients treated with simvastatin were significantly older and were pre-
scribed more drugs than other statin users. 
The distribution of drugs concomitantly prescribed with statins is shown in Table 
5.2. Since arterial hypertension and coronary heart disease were the most prevalent co-
morbidities, acetylsalicylic acid, betablockers, ACE-inhibitors, angiotensin receptor blo-
ckers, and thiazide or loop diuretics were the drugs most often prescribed concomitant-
ly. Overall, 122 patients (4.4%) had no additional drug prescribed. 
Overall, 190 (6.9%) of the 2742 patients with statin therapy had a total of 198 drug 
combinations with the potential for a critical drug-statin interaction; eight patients had 
two such drug combinations (see Table 5.3). The prevalence of potentially critical drug-
statin interactions was 12.1% (95% CI 9.7 to 14.4%) in patients with simvastatin, 10.0% 
(95% CI 8.0 to 12.1%) with atorvastatin, 3.8% (95% CI 0.5 to 7.1%) with fluvastatin, and 
0.3% (95% CI 0.1 to 0.7%) with pravastatin. The potentially interacting drugs comprised 
other lipid lowering drugs (fibrates, nicotinic acid), known CYP 3A4 inhibitors (amio-
darone, verapamil, fluoxetine / norfluoxetine, diltiazem, nefazodone, clarithromycin and 
systemic azole antifungal drugs), or known CYP2C9 inhibitors (fluoxetine / norfluoxe-
tine). Forty-three patients (22.6% of the patients with a potential drug-statin interaction) 
were concomitantly treated with digoxin, a P-gp substrate.  
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Logistic regression analysis indicated that the following variables were asso-
ciated with a statistically increased relative risk for potentially critical drug-statin interac-
tions: Number of drugs (adjusted OR 1.3; 95% CI 1.2 to 1.4, p < 0.001), diagnosis of 
cardiac failure (adjusted OR 1.8; 95% CI 1.1 to 3.1, p = .03), diagnosis of arrhythmias 
(adjusted OR 5.6; 95% CI 3.6 to 8.5, p < 0.001), and being a patient from the French 
speaking part of Switzerland (adjusted OR 1.5; 95% CI1.1 to 2.1, p = 0.018). The use of 
pravastatin was associated with a lower risk for potentially critical drug-statin interacti-
ons (adjusted OR = 0.02, 95% confidence interval 0.01 to 0.07, p < 0.001) compared to 
use of other statins. 
Additional drug-statin combinations were observed, which did not meet the criteria 
to be classified as potential DDIs with harmful clinical consequences as defined, but 
which are worth mentioning. Three hundred and twenty patients (11.7% of the study 
population) were prescribed an oral anticoagulant, either phenprocoumon (CYP3A4 and 
CYP2C9 substrate; 201 patients or 7.3% of all patients studied) or acenocoumarol (CYP 
2C9 substrate; 119 patients or 4.3%). In 200 patients (7.3%) oral anticoagulants were 
administered in combination with atorvastatin, simvastatin or fluvastatin. Since oral anti-
coagulants are only CYP substrates but not inhibitors, these potential interactions were 
not included in our analysis. Fifty-four patients (2.0 % of all patients studied) were trea-
ted with a CYP inducer. Thirty-nine of these patients (1.4%) had a combination which 
might lead to a decreased plasma concentration of the statin (simvastatin or atorvasta-
tin) and a potential loss of its clinical effect (7 with barbiturates, 15 with carbamazepine, 
2 with phenytoin, and 15 with St. Johns wort). Since the clinical relevance of these po-
tential interactions is not clear, they were not included in our analysis. The potential in-
teraction between atorvastatin and clopidogrel, which was initially published in early 
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2003 (27) remains controversial (28, 29) and was therefore not included in our a-
nalysis. No patient was reported to have signs or symptoms of myopathy during data 
collection. 
 
5.4.2 Non-statin DDIs 
In 288 patients of 2742 patients studied (10.5%), 393 drug combinations with non-
statin DDIs were identified, corresponding to a mean of 1.36 ± 0.8 interactions per affec-
ted patient. Of 288 patients with interactions, 219 (76.0%) had one non-statin DDI, 47 
patients (16.3%) had two and 22 patients (7.6%) had three or more non-statin DDIs. 
The non-statin DDIs which were detected most often are listed in Table 5.4. Patients 
treated with ACE-inhibitors, potassium sparing diuretics, betablockers, oral anticoagu-
lants, amiodarone or digoxin were most likely to have potential non-statin DDIs. The un-
derlying mechanism of potential DDIs was pharmacodynamic in 65% of the 393 drug 
combinations with non-statin DDIs (predominantly among cardiovascular drugs), 14% 
were pharmacokinetic, and in 21% the mechanism was unclear. 
Logistic regression analysis yielded statistically increased relative risks for the fol-
lowing variables: Male sex (adjusted OR 1.4; 95% CI 1.1 to 1.9), number of prescribed 
pharmacologically active compounds (adjusted OR 1.6; 95% CI 1.5 to 1.7), diagnosis of 
cardiac failure (adjusted OR 3.3; 95% CI 2.1 to 5.1), diagnosis of arrhythmias (adjusted 
OR 3.50; 95% CI 2.4 to 5.2), diagnosis of cerebrovascular diseases (adjusted OR 1.6; 
95% CI 1.1 to 2.2), and a diagnosis of gout (adjusted OR 2.9; 95% CI 1.7 to 4.9). 
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5.5 Discussion 
Our study demonstrates that overall, approximately 7% of all patients prescribed a 
statin have a potentially critical drug-statin interaction. This figure is lower than the one 
obtained in a recent study in Ireland, where potentially interacting drugs were detected 
in approximately 30% of patients treated with a statin (12). This discrepancy may be 
explained by differences in the prescribing pattern between Ireland and Switzerland and 
also by differences in the definition of drug-statin interactions. Considering the prescri-
bing pattern, only 3.6% of the patients in our study were treated with the CYP3A4 inhibi-
tors verapamil or diltiazem, whereas 13.1% of the patients in the Irish study were con-
comitantly treated with these drugs (12). In the Irish study, inhibitors, inducers and sub-
strates of CYP3A4 and CYP2C9 were regarded as drugs potentially interacting with sta-
tins (12). In contrast, in our study, only CYP inhibitors, P-gp substrates and other drugs 
for which case reports or drug interaction studies about a clinically relevant interaction 
could be identified, were considered as drugs potentially interacting with statins. Moreo-
ver, CYP3A4 and/or CYP 2C9 substrates, for which no case reports of clinically relevant 
drug-statin interactions exist, were not included in the analysis. In addition, CYP indu-
cers (e.g. phenytoin, carbamazepin, rifampicin and St. Johns wort) were not considered 
as drugs with a clinically significant interaction potential with statins in our study, and 
were therefore not included. 
Although the participating physicians had been told to transmit the medication lists 
of the patients entering the study before performing any changes, we cannot exclude 
the possibility that some practitioners checked the medication list for drug-drug interac-
tions before transmitting it. The true prevalence of drug-drug interactions may therefore 
be higher than found in our study. 
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Approximately 40% of all patients treated with a statin who develop rhabdo-
myolysis are concomitantly treated with an interacting drug (18). A recent analysis of 
reports to the FDA revealed that mibefradil, fibrates, cyclosporine, macrolides (erythro-
mycin and clarithromycin), warfarin, digoxin, azole antifungals, nicotinic acid, tacrolimus, 
chlorzoxazone and nefazodone were the drugs or drug classes considered to be invol-
ved in statin-induced rhabdomyolysis. From our data, showing that 7% of patients trea-
ted with a statin have a potential drug-statin interaction, it can be estimated that drug-
statin interactions increase the risk for rhabdomyolysis by a factor of approximately 6. 
This figure corresponds well with an estimated 10-fold increase in the risk of rhabdomy-
olysis reported by Omar et al. (18), confirming our findings and calculations. Statin-
induced rhabdomyolysis remains therefore a rare event, occurring in 0.04-0.2% of statin 
treated patients, even in the presence of an interacting drug (18). This is supported by 
the observation that none of the 2742 patients studied, including the 190 patients with a 
potential drug-statin interaction, had signs or symptoms of myopathy in our investigati-
on. Despite being a rare adverse reaction, due to the widespread use of statins and the 
potentially fatal outcome, statin-associated rhabdomyolysis has become an important 
clinical problem. This was demonstrated dramatically by the recent withdrawal of ceri-
vastatin from the market (30). 
Our study defines several risk factors associated with the presence of a potentially 
critical drug-statin interaction. The individual statin chosen for treatment of dyslipidemia 
is the most important one. Similar to other epidemiological studies (12, 31) and publis-
hed case series of patients with statin-induced rhabdomyolysis (18), our study also de-
monstrates that CYP3A4 inhibitors concomitantly prescribed with simvastatin or ator-
vastatin (lovastatin is not marketed in Switzerland), are the most frequent combinations 
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of potentially critical drug-statin interactions. Potential drug interactions with flu-
vastatin are rarer, because this drug is primarily metabolized by CYP2C9 (13, 32), 
CYP2C9 inhibitors are less often used in dyslipidemic patients than CYP3A4 inhibitors 
(12). For pravastatin, potential interactions seem to be even rarer than for fluvastatin, 
since this statin is not metabolized by CYP450 enzymes, but is glucuronidated. 
Furthermore, the study shows that important additional risk factors for the appea-
rance of potentially critical drug interactions with statins include the number of concomi-
tant drugs a patient is prescribed, and a diagnosis of heart failure and/or arrhythmias; 
these diagnoses are highly correlated with specific drug therapies known to interact with 
statins. In the case of heart failure, an important interaction is observed between statins 
and digoxin, which can increase the plasma digoxin level by approximately 30% due to 
inhibition of P-gp by certain statins. This interaction is observed with P-gp substrates 
such as simvastatin, lovastatin, and atorvastatin (33). Regarding the narrow therapeutic 
range of digoxin, this interaction may be clinically relevant for the above mentioned sta-
tins, but not with pravastatin (34), which does not inhibit P-gp (33, 35). 
The group of patients with the highest risk for potential drug-statin interactions is 
those with cardiac arrhythmias. In Switzerland, patients with cardiac arrhythmias are of-
ten treated with verapamil, digoxin or amiodarone, which can all interact with most sta-
tins. Verapamil inhibits both CYP3A4 and P-gp (35, 36), and amiodarone is an efficient 
inhibitor of several CYPs, among them CYP3A4 and CYP2C9 (37). 
The interactions between statins and fibrates or cyclosporine may be mediated by 
the inhibition of hepatic transporters, which are involved in the hepatic uptake of statins. 
OATP2/OATP-C-mediated transport has been identified not only for pravastatin (38, 
39), but also for simvastatin (38), fluvastatin (38), atorvastatin (40) and cerivastatin (41). 
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Shatira et al. showed that cyclosporine can inhibit hepatic uptake of cerivastatin, 
which was at least partly mediated by cyclosporine-induced inhibition of OATP2, sug-
gesting that increased plasma levels of cerivastatin in the presence of cyclopsorine are 
mainly due to impairment of hepatic uptake than inhibition of CYP3A4 (41). The same 
mechanism may be responsible for the DDI with cyclosporine and pravastatin (42). Re-
cently, the pharmacokinetic interaction between gemfibrozil and pravastatin has been 
investigated in more detail. The increase in the pravastatin plasma concentration could 
be explained by both a decrease in renal clearance and in hepatic uptake (43). 
As expected and as shown in previous studies (44, 45), we could identify po-
lypharmacy as a risk factor for DDIs. In agreement with these studies, the current work 
also demonstrates that the risk for potentially serious DDIs increased with the increa-
sing number of drugs used. This may be critical in particular in patients with cardiac di-
seases, who are generally treated with more than one drug (46). Accordingly, we identi-
fied heart failure as one of the major risk factors associated with potential non-statin 
DDIs. Regarding the drugs used in heart failure, for instance ACE-inhibitors, digoxin, 
and potassium-sparing and loop diuretics, they all rank among the drugs with a high 
prevalence of potentially serious non-statin DDIs. 
Potential non-statin interactions frequently detected in patients with heart failure 
were those between ACE-inhibitors and potassium supplements or potassium-sparing 
diuretics which is in accordance with a study of the prevalence of DDIs in the medicati-
on of medical patients at hospital discharge (20). While the administration of potassium 
supplements in patients treated with ACE-inhibitors is well known to be associated with 
hyperkalemia (47, 48), the development of hyperkalemia in patients treated with ACE-
inhibitors and low dose spironolactone, i.e. 25-50 mg/day as recommended for the 
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treatment of heart failure (49), has been reported only recently (50, 51). Renal fai-
lure appears to be an additional risk factor for the development of hyperkalemia in pati-
ents treated with ACE-inhibitors, in particular when a drug-drug and/or diet-drug interac-
tion is present (50, 52). Concomitant use of loop or thiazide diuretics may diminish the 
risk of hyperkalemia of ACE inhibitors and potassium supplements or potassium-sparing 
diuretics, but we still recommend that patients treated with such combinations should be 
followed carefully, in particular if they also have renal failure. 
Another group of patients with a high prevalence of non-statin DDIs identified in 
our study are those with gout. Our data indicate that this is the case particularly becau-
se of a potential interaction between allopurinol and ACE-inhibitors, which may increase 
the risk of developing an allopurinol-induced hypersensitivity syndrome (53). While e-
xamples for this interaction only exist as case reports (54-56), the clinical outcome for 
the allopurinol-associated hypersensitivity syndrome is potentially so serious (fatalities 
are reported (53, 57, 58)) that it may be prudent to avoid this drug combination. 
Patients with psychiatric disorders, in particular depression, were also identified as 
risk group for non-statin DDIs. While tri- and tetracyclic antidepressants are generally 
not relevant inhibitors or inducers of CYPs, this is different for selective serotonin reup-
take inhibitors (SSRIs) (59). Significant inhibition of CYPs have been described for flu-
voxamine (inhibition of CYP1A2, CYP2C19 and CYP3A4), paroxetine (CYP2D6) and 
fluoxetine (CYP2D6, CYP1A2, CYP3A4 and CYP2C9) (59-61). For all of these SSRIs, 
DDIs due to CYP inhibition with clinical relevance have been described. This is impor-
tant to know for physicians caring for patients with cardiovascular disease, since anti-
depressants are frequently prescribed in this population (62). 
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None of the patients included in this study had symptoms or signs of an ad-
verse drug effect due to a statin or non-statin DDI. Regarding other reports in the litera-
ture, where approximately 6% of patients with a critical DDI have adverse effects (63, 
64), some adverse effects in the 190 patients with statin interactions or the 288 patients 
identified with a critical non-statin DDI would have been expected. However, the aim of 
the study was to quantify the prevalence of potential DDIs and not of adverse events. 
Additionally, we did not have direct access to the patient records to identify adverse cli-
nical outcomes in association with a DDI, potentially favoring underreporting of DDI-
associated adverse reaction. Moreover, the medication screened included only those 
drugs prescribed by the physician taking part in the study. It is possible that patients 
may have visited other physicians prescribing additional drugs that were unknown to the 
physician treating the patient for dyslipidemia. Therefore, the prevalence of potential 
statin or non-statin DDIs in this population may be even higher than the one assessed in 
this study. 
 
5.6 Conclusions 
In conclusion, our study shows that CYP3A4 inhibitors are the most frequent cau-
se of potential drug interactions with statins. Although statin-induced rhabdomyolysis is 
a rare event even in patients having a drug-statin interaction, the possibly severe out-
come of rhabdomyolysis favors the concept that potentially interacting drug-statin com-
binations should be avoided or patients should be monitored more closely. It is therefore 
important to teach clinicians about the most frequently observed drug-statin interactions 
and how these interactions can be avoided. 
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Additionally, serious non-statin DDIs are common in patients with dyslipide-
mia, mostly due to co-morbidities for which they are treated concomitantly with nume-
rous additional drugs. Further research is necessary to assess the clinical significance 
of our findings, e.g. the incidence and clinical significance of adverse effects in patients 
with potentially serious DDIs. 
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Table 5.1 Patient characteristics and co-morbidities in 2742 dyslipdemic patients with statin therapy stratified according to individual 
statins 
Patients Total 
(n=2742) 
Atorvastatin 
(n=886) 
Pravastatin 
(n=934) 
Simvastatin 
(n=763) 
Fluvastatin 
(n=159) 
p-value 
Age, yrs (mean ± SD) 65.1 ± 11.2 63.7 ± 11.6 65.3 ± 11.2 66.5 ± 10.8 65.6 ± 10.8 <.05* 
Females, n (%) 1052 (38.4) 334 (37.7) 362 (38.8) 296 (38.8) 60 (37.7) ns 
Number of diagnoses (including 
dyslipidemia) (mean ± SD) 
3.2 ± 1.6 3.2 ± 1.6 3.2 ± 1.6 3.4 ± 1.5 3.2 ± 1.3 ns 
Number of prescribed drugs inc-
luding statin (mean ± SD) 
4.9 ± 2.4 4.7 ± 2.4 4.8 ± 2.4 5.1 ± 2.3 5.1 ± 2.2 <.05 † 
Hypertension, n (%) 1428 (52.1) 441 (49.8) 479 (51.3) 407 (53.3) 101 (63.5) ns 
Diabetes mellitus, n (%) 520 (19.0) 170 (19.2) 170 (18.2) 151 (19.8) 29 (18.2) ns 
Coronary heart disease, n (%) 1166 (42.5) 372 (42.0) 389 (41.6) 348 (45.6) 57 (35.8) ns 
Cardiac failure, n (%) 130 (4.7) 40 (4.5) 35 (3.7) 49 (6.4) 6 (3.8) ns 
Arrhythmias, n (%) 188 (6.9) 56 (6.3) 63 (6.7) 61 (8.0) 8 (5.0) ns 
Cerebrovascular diseases  461 (16.8) 136 (15.3) 159 (17.0) 139 (18.2) 27 (17.0) ns 
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Patients Total 
(n=2742) 
Atorvastatin 
(n=886) 
Pravastatin 
(n=934) 
Simvastatin 
(n=763) 
Fluvastatin 
(n=159) 
p-value 
(including transitory ischemic at-
tacks and peripheral arterial occ-
lusive disease), n (%) 
Depression/psychiatric disorder,  
n (%) 
423 (15.4) 137 (15.5) 133 (14.2) 125 (16.4) 28 (17.6) ns 
Rheumatic diseases / diseases of 
musculoskeletal system, n (%) 
416 (15.2) 124 (14.0) 139 (19.9) 128 (16.8) 25( 15.7) ns 
Gout / hyperuricemia, n (%) 103 (3.8) 42 (4.7) 34 (3.6) 21 (2.8) 6 (3.8) ns 
Epilepsy, n (%) 16 (0.6) 4 (0.5) 6 (0.6) 6 (0.8) 0 ns 
Other diagnoses, n (%) 244 (8.9) 88 (9.9) 94 (10.1) 54 (7.1) 8 (5.0) ns 
 
* Age: simvastatin > atorvastatin (p < 0.05 by ANOVA/Bonferroni-Holm) 
† Number of drugs: simvastatin > atorvastatin, simvastatin > pravastatin (p < 0.05 by ANOVA/Bonferroni-Holm) 
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Table 5.2 Comedication prescribed in 2742 statin users stratified according to individual statin 
 
Total 
(n=2742) 
Atorvastatin 
(n=886) 
Pravastatin 
(n=934) 
Simvastatin 
(n=763) 
Fluvastatin 
(n=159) 
p-value 
Number of concomitant drugs 
(mean ± SD) 
3.9 ± 2.4 3.7 ± 2.4 3.8 ± 2.4 4.1 ± 2.3 4.1 ± 2.2 <0.05 † 
Acetylsalicylic acid, n (%) 1258 (45.9) 423 (47.7) 408 (43.7) 366 (48.0) 57 (35.8) ns 
Betablockers, n (%) 1145 (41.8) 373 (42.1) 376 (40.3) 327 (42.9) 69 (43.4) nt 
Thiazide or loop diuretics, n (%) 900 (32.8) 272 (30.7) 320 (34.3) 258 (33.8) 50 (31.4) ns 
ACE-inhibitors, n (%) 778 (28.4) 226 (25.5) 250 (26.8) 252 (33.0) 50 (31.4) <0.05 & 
Angiotensin receptor antagonists, 
n (%) 
551 (20.1) 177 (20.0) 198 (21.2) 147 (19.3) 29 (18.2) nt 
Non-steroidal anti-inflammatory 
drugs, n (%) 
427 (15.6) 122 (13.8) 140 (15.0) 132 (17.3) 33 (20.8) ns 
Calcium antagonists, n (%)  
(dihydropyridines) 
403 (14.7) 129 (14.6) 130 (13.9) 121 (15.9) 23 (14.5) nt 
Antidepressants*, n (%) 340 (12.4) 119 (13.4) 88 (9.4) 103 (13.5) 30 (18.9) <0.05 $ 
  
87 
 
Total 
(n=2742) 
Atorvastatin 
(n=886) 
Pravastatin 
(n=934) 
Simvastatin 
(n=763) 
Fluvastatin 
(n=159) 
p-value 
Oral antidiabetics (other than  
sulfonylureas, n (%) 
238 (12.0) 119 (13.4) 111 (11.9) 84 (11.0) 14 (8.8) nt 
Sulfonylureas, n (%) 205 (7.5) 70 (7.9) 67 (7.2) 58 (7.6) 10 (6.3) nt 
Phenprocoumon, n (%) 201 (7.3) 56 (6.3) 76 (8.1) 62 (8.1) 7 (4.4) ns 
Potassium sparing diuretics, n (%) 161 (5.9) 57 (6.4) 53 (5.7) 38 (5.0) 13 (8.2) nt 
Clopidogrel, n (%) 136 (5.0) 43 (4.9) 37 (4.0) 48 (6.3) 8.0 (5.0) nt 
Insulin, n (%) 133 (4.9) 40 (4.5) 40 (4.3) 45 (5.9) 8 (5.0) nt 
Allopurinol, n (%) 122 (4.4) 43 (4.9) 42 (4.5) 27 (3.5) 10 (6.2) nt 
Acenocoumarol, n (%) 119 (4.3) 27 (3.0) 44 (4.7) 41 (5.4) 7 (4.4) ns 
Calcium antagonists (verapamil or 
diltiazem), n (%) 
100 (3.6) 33 (3.7) 30 (3.2) 31 (4.1) 6 (3.8) nt 
Amiodarone, n (%) 82 (3.0) 29 (3.2) 26 (2.8) 23 (3.0) 4 (2.5) ns 
Digoxin, n (%) 67 (2.4) 21 (2.4) 19 (2.0) 23 (3.0) 4 (2.5) nt 
Tramadol , n (%) 24 (0.9) 12 (1.4) 5 (0.5) 7 (0.9) -- nt 
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Total 
(n=2742) 
Atorvastatin 
(n=886) 
Pravastatin 
(n=934) 
Simvastatin 
(n=763) 
Fluvastatin 
(n=159) 
p-value 
St. Johns wort, n (%) 23 (0.8) 8 (0.9) 8 (0.9) 5 (0.7) 2 (1.3) nt 
Gingko, n (%) 18 (0.7) 5 (0.5) 9 (1.0) 4 (0.5) -- nt 
Fibrates, n (%) 17 (0.6) 10 (1.1) 3 (0.3) 3 (0.4) 1 (0.6) nt 
Cyclosporine, n (%) 8 (0.3) -- 4 (0.4) 3 (0.4) 1 (0.6) nt 
Methotrexate, n (%) 6 (0.2) 2 (0.2) 2 (0.2) -- 2 (1.3) nt 
Azathioprin, n (%) 4 (0.1) -- 1 (0.1) 3 (0.4) -- nt 
Nicotinic acid, n (%) 3 (0.1) -- 2 (0.2) 1 (0.1) -- nt 
Azole antifungals (systemic), n (%) 2 (0.1) -- -- 2 (0.3) -- nt 
 
*excluding St. Johns wort extract 
nt = not tested to avoid multiple testing on the same sample. 
† Number of drugs: simvastatin > atorvastatin, simvastatin > pravastatin (p < 0.05 by ANOVA/Bonferroni-Holm) 
& ACE-inhibitors: simvastatin > atorvastatin; simvastatin > pravastatin (p < 0.05 by ANOVA/Bonferroni-Holm) 
$ Antidepressants: atorvastatin > pravastatin; fluvastatin > pravastatin (p < 0.05 by ANOVA/Bonferroni-Holm) 
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Table 5.3 List of 198 potential drug-statin interactions in 190 dyslipidemic patients treated with a statin; eight patients had two potential 
interactions (7 in the atorvastatin and 1 in the simvastatin group) 
Potential interactions Total Atorvastatin Pravastatin Simvastatin Fluvastatin 
Total number of patients with po-
tential interactions, n  
190  89  3  92  6  
Total number of potential interac-
tions, n (%) 
198 (100.0) 96 (100.0) 3 (100.0) 93 (100.0) 6 (100.0) 
Other lipid lowering drugs, n (%) 18 (9.1) 10 (10.4) 3 (100.0) 4 (4.3) 1 (16.7) 
Fibrates 17 (8.6) 10 (10.4) 3 (100.0) 3 (3.2) 1 (16.7) 
Nictotinic Acid 1 (0.5) -- -- 1 (1.1) -- 
CYP3A4 inhibitors, n (%) 129 (65.2) 66 (68.8) NA 63 (67.7) NA 
Amiodarone 52 (26.3) 29 (30.2) -- 23 (24.7) -- 
Verapamil 40 (20.2) 21 (21.96) -- 19 (20.4) -- 
Diltiazem 5 (2.5) -- -- 5 (5.4 -- 
Fluoxetin / Norfluoxetin 24 (12.1) 13 (13.5) -- 11 (11.8) -- 
Nefazodone 3 (1.5) 3 (3.1) -- -- -- 
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Potential interactions Total Atorvastatin Pravastatin Simvastatin Fluvastatin 
Clarithromycin 3 (1.5) -- -- 3 (3.2) -- 
Azole antifungal (systemic) 2 (1.0) -- -- 2 (2.2) -- 
CYP2C9 inhibitors, n (%) 5 (2.5) NA NA NA 5 (83.3) 
Fluoxetin / Norfluoxetin 5 (2.5) -- -- -- 5 (83.3) 
P-gp substrates, n (%) 43 (21.7) 20 (20.8) NA 23 (24.7) -- 
Digoxin 43 (21.7) 20 (20.8) -- 23 (24.7) -- 
Others, n (%) 3 (1.5) -- -- 3 (3.2) -- 
Cyclosporine 3 (1.5) -- -- 3 (3.2) -- 
 
NA = not applicable 
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Table 5.4 Description of 393 critical non-statin drug-drug interactions in 288 patients with dyslipidemia 
Interaction n (%) Mechanism and/or potential risk 
ACE-inhibitor – potassium sparing 
diuretic 
51 (13.0) Hyperkalemia due to increased potassium retention secondary to lowered aldosterone 
levels caused by ACE-inhibitor 
Digoxin – loop / thiazide diuretics 42 (10.7) Secondary digoxin toxicity due to diuretic-induced hypokalemia and hyomagnesemia, 
enhancing Na-K-ATPase inhibition by cardiac glycosides 
Allopurinol – ACE-inhibitor 40 (10.2) Unknown mechanism leading to hypersensitivity syndrome 
Amiodarone – oral anticogualants 
(phenprocoumon, acenocoumarol) 
33 (8.4) Increased bleeding risk due to decreased metabolism of oral anticoagulants 
Amiodarone – betablocker 31 (7.9) Additive cardiac effects (AV node refractory period prolonged and sinus node automati-
city decreased by amiodarone), potentially leading to bradycardia, hypotension or cardi-
ac arrest 
Aspirin – oral anticoagulant (phen-
procoumon, acenocoumarol) 
27 (6.9) Combination of thrombocyte aggregation inhibition and anticoagulant is associated with 
increased risk of bleeding  
Betablocker – antidiabetic agents 22 (5.6) Blockade of β2-receptors impairs glycogenolysis and peripheral manifestations of hy-
poglycaemia (described for insulin or sulfonylureas, but not for thiazolidindiones, acar-
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Interaction n (%) Mechanism and/or potential risk 
bose or metformin) 
Digoxin – betablocker 21 (5.3) Additive prolongation of AV-conduction time. 
Digoxin toxicity due to competition for intestinal P-gp (described for talinolol) 
Diltiazem / verapamil – betablocker 18 (4.6) Additive negative inotropic effects and impaired AV conduction possibly leading to  
hypotension, bradycardia and conduction blocks 
Gingko – aspirin / oral anticoagulants 
(phenprocoumon, acenocoumarol) 
16 (4.1) Increased risk of bleeding due to inhibition of thrombocyte aggregation by gingko  
NSAID – aspirin 13 (3.3) Increased risk of gastrointestinal bleeding in patients with NSAID and low dose aspirin 
NSAID – oral anticoagulants 
(phenprocoumon, acenocoumarol) 
11 (2.8) Increased risk of gastrointestinal bleeding due to gastric erosions, inhibition of platelet 
aggregation and displacement of anticoagulants from plasma albumin by NSAID 
Tramadol – CNS-drugs tricyclic anti-
depressants, selective serotonine 
reuptake inhibitors (SSRI), neurolep-
tics, monoamine oxidase inhibitors 
(MAO) 
10 (2.5) Decreased seizure threshold and enhanced risk for seizures in combination with CNS 
drugs associated with seizures 
Increased concentration of serotonin in the nervous system and periphery potentially 
leading to serotonin syndrome 
Hypertensive crisis in combination with MAO-inhibitors 
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Interaction n (%) Mechanism and/or potential risk 
CYP inducers* (phenobarbital, primi-
done, phenytoin, carbamazepine,  
hypericum, rifampicin ) – critical CYP 
substrates* (phenprocoumon, aceno-
coumarol, clonazepam, clozapin,  
antiepileptics) 
9 (2.3) Clearance of CYP substrates increased  
CYP inhibitors* (amiodarone, fluoxe-
tine, fluvoxamine) – critical CYP sub-
strate* (thioridazine, cisaprid, vera-
pamil, alprazolam, amitriptylin) 
7 (1.8) Clearance of CYP substrates decreased  
Potassium – ACE-inhibitors 6 (1.5) Increased potassium retention and risk for hyperkalemia secondary to lowered aldoste-
rone levels caused by ACE-inhibitor 
Potassium – potassium sparing  
diuretics 
5 (1.3) Increased potassium retention and risk for hyperkalemia 
Methrotrexate - NSAID 5 (1.3) Increased MTX toxicity due to decreased renal methrotrexate clearance due to NSAID 
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Interaction n (%) Mechanism and/or potential risk 
induced impairment of renal perfusion and competition of tubular secretion 
other 26 (6.6) NA 
 
* = the drugs listed (CYP inducers, CYP substrates, CYP inhibitors) contain the drugs which were prescribed during the current study. The list 
does therefore not necessarily contain the typical drugs interacting with CYPs. 
NA = not applicable 
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6.1 Summary 
 Dose adaptation for liver disease is important in patients treated with antine-
oplastic drugs due to the high prevalence of impaired liver function in this population 
and the dose-dependent, frequently serious adverse effects of these drugs. We clas-
sified the antineoplastic drugs marketed in Switzerland by the end of the year 2003 
according to their bioavailability/hepatic extraction in order to predict their kinetic be-
havior in patients with decreased liver function. This prediction was compared with 
kinetic studies carried out with these drugs in patients with liver disease. The studies 
were identified by a structured, computer-based literature search. 
 Of the 69 drugs identified, 52 had a predominant extrarenal (in most cases hepa-
tic) metabolism and/or excretion. For 48 drugs, hepatic extraction could be calculated 
and/or bioavailability was available, allowing classification according to hepatic 
extraction. For 17 drugs, kinetic studies have been reported in patients with impaired 
liver function, with the findings generally resulting in quantitative recommendations 
for adaptation of the dosage. In particular, recommendations are precise for 13 drugs 
excreted by the bile (e.g. doxorubicin and derivatives, and vinca alkaloids). Validation 
studies comparing such recommendations with kinetics and/or dynamics of antine-
oplastic drugs in patients with decreased liver function have not been published. 
 We conclude that there are currently not enough data for safe use of cyctostatics 
in patients with liver disease. Pharmaceutical companies should be urged to provide 
kinetic data (especially hepatic extraction) used for classification of such drugs and to 
conduct kinetic studies for drugs with primarily hepatic metabolism in patients with 
impaired liver function allowing to give quantitative advise for dose adaptation. 
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6.2 Introduction 
Dose adaptation for patients with liver disease is more difficult than for patients 
with impaired renal function. The main reason for this statement is the fact that, unli-
ke the creatinine clearance for the kidney, for the liver there is no in vivo surrogate to 
predict drug clearance. Due to the lack of such in vivo markers, predictions concer-
ning dose adaptation in patients with liver disease can only be made based on the 
kinetic properties of the drugs to be administered and on kinetic studies of such 
drugs in patients with liver disease. 
 Several reviews have covered this subject during the last years (1-5). In these 
reviews, drugs are listed according to pharmacokinetic variables which are derived 
from the hepatic clearance of drugs. The hepatic clearance (Clhep) of a drug is given 
by: 
 
Q)Clf(
Q)Clf(Cl
iu
iu
hep +×
××
=    (1) 
 
where fu is the unbound fraction and Cli the intrinsic clearance of a drug, respectively, 
and Q the blood flow across the liver. Cli represents the maximal capacity of the liver 
to metabolize a given drug, not taking into account limitations by liver perfusion (6). 
Cli can therefore reach values which are larger than Q, which is important for un-
derstanding the special situations discussed below. 
 Equation (1) can be simplified for the two extremes (fu x Cli) >> Q or Q >> (fu x 
Cli). For the first case, (fu x Cli) >> Q, the denominator in equation (1) simplifies to (fu 
x Cli), and Clhep equals: 
 
QClhep =  (2) 
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For such drugs, the liver has a very large metabolic capacity, and the blood flow 
across the liver becomes rate-limiting for hepatic clearance. These drugs are therefo-
re called “flow-limited” or “high capacity” and are usually cleared by the liver to a sub-
stantial degree already during the first hepatic passage. Therefore, they have a high 
hepatic extraction or a low bioavailability. Since portal blood is impaired in patients 
with liver cirrhosis (7, 8), hepatic clearance of such drugs is decreased, necessitating 
a reduction of the maintenance dose in this group of patients. A second potential 
problem of such drugs is an increase in bioavailability when they are administered 
orally. Since these drugs have a low bioavailability by definition, an increase in bioa-
vailability could lead to toxic blood levels. This can be expected to happen in patients 
with porto-systemic shunts, which result from portal hypertension due to liver cirrho-
sis or fibrosis or, of importance in patients with cancer, due to multiple metastases (9, 
10). Therefore, when such drugs are administered orally, the initial and the mainte-
nance doses have to be reduced according to the expected increase in bioavailability 
and to the decrease in hepatic blood flow. For intravenous administration, only the 
maintenance dose has to be reduced according to the impairment in hepatic blood 
flow. A list of such drugs is given in a previous publication (1). 
For the second type of drugs, Q >> (fu x Cli), the metabolic capacity of the liver 
is much lower than blood flow across the liver. Equation (1) therefore simplifies to: 
 
)Clf(Cl iuhep ×=    (3) 
 
These drugs are therefore called “low extraction” or “capacity-limited”. They have not 
a high extraction during the first passage across the liver and have therefore a high 
bioavailability, if bioavailability is not limited by other processes than first pass hepa-
tic metabolism and/or biliary excretion. Since Cli decreases for most drugs in patients 
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with liver cirrhosis due to a decrease in the activity of cytochrome P450 isozymes 
(CYP) (11, 12) and/or glucuronyl transferases (13-15), the maintenance dose of such 
drugs has generally to be decreased. For drugs with a high binding to albumin 
(>90%), the situation may be more complex. The free fraction (fu) and the free con-
centration of such drugs can increase in patients with a low serum albumin con-
centration, e.g. patients liver cirrhosis or malnourished patients such as patients with 
cancer. An increase in the free concentration and/or fu of such drugs may be associa-
ted with increased toxicity, and, as shown in equation 3, also with an increased hepa-
tic clearance (16, 17). The actual hepatic clearance of such drugs is therefore difficult 
to predict in patients with chronic liver disease.  
In between of these two extremes, there are drugs with an “intermediate ex-
traction”, showing characteristics of both groups. The dosage advice for such drugs 
in patients with liver cirrhosis is to start with a low dose and to up-titrate carefully in 
order to find the correct maintenance dose. 
Regarding dose adaptation in patients with cancer, it has to be recognized, 
however, that the dosing guidelines discussed above focus on patients with liver 
cirrhosis or fibrosis, but not on patients with increased transaminases and/or cho-
lestasis which are found frequently among patients treated with antineoplastic drugs. 
Since the majority of antineoplastic drugs is metabolized by the liver (see Table 6.3) 
and is associated with severe dose-dependent toxicity, the question whether the do-
se has to be adapted in a patient with increased transaminases and/or cholestasis 
appears to be an important one. The most prevalent liver disease in this group of pa-
tients is the presence of liver metastases, possibly resulting in cholestasis and/or por-
tal hypertension (10, 18, 19). Since many antineoplastic drugs are potentially hepato-
toxic themselves (see Table 6.3), drug-induced liver disease may also be common in 
patients undergoing repetitive cycles of chemotherapy. On the other hand, with the 
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exception of hepatocellular carcinoma, liver cirrhosis is probably not more prevalent 
in patients with cancer as compared to an age-matched population without cancer, 
but no exact data are available. 
 The aims of the current study were therefore 1) to categorize the antine-
oplastic drugs used according to pharmacokinetic criteria as discussed above 2) to 
compare this categorization with the dose recommendations in patients with liver di-
sease given in the standard literature 3) to create a table with the current recommen-
dations for dose adaptation 4) to localize gaps in the current recommendations. 
 
6.3 Methods 
 We screened Medline and Embase for studies dealing with dose adaptation and 
hepatic adverse effects for all antineoplastic drugs which were on the market in Swit-
zerland by the end of the year 2003. The data bases were screened using the follo-
wing MESH terms: antineoplastic agents, drug toxicity, pharmacokinetics, liver disea-
ses. The references detected by the search in the databases were screened for other 
references dealing with the subjects. In addition to databases, the standard literature 
was screened for dose adaptation recommendations and adverse effects on the liver, 
including the “Swiss Compendium of Drugs” (20) (similar to the “Physicians’ Desk 
Reference” (21)), “Therapeutic drugs” of Dollery et al. (22) and “Hepatotoxicity” of H. 
J. Zimmerman (23). 
 The antineoplastic drugs were categorized according to pharmacokinetic prin-
ciples as outlined in the introduction and based on the reviews of Huet and Villeneu-
ve (16) and Krähenbühl and Reichen (1). The categorization system used is based 
on the hepatic extraction or bioavailability, and protein binding of the specific drugs 
(see  
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Table 6.1). Values for bioavailability and protein binding could be found either in the 
original articles (cited in Table 6.3) or in other sources (20-22, 24). For hepatic 
extraction, data in the literature are rare, making it necessary to estimate extraction 
from bioavailability (see  
Table 6.1) or by the following equation: 
 
Q
ClQ
E sys
×
=
0
   (4) 
 
where Q0 is the extrarenal dose fraction (the fraction of a drug which is not excreted 
unchanged by the kidney), Clsys the systemic clearance and Q the blood flow across 
the liver. Most of the values for E in Table 6.3 are estimated using this equation. The 
values for Q0 and Clsys were obtained from the literature (20-22, 25), and Q was as-
sumed to be 1.5 L/min. 
 Dosage recommendations originate either from the original articles or from the 
manufacturer as published in the PDR (21) and/or the Swiss Compendium of Drugs 
(20). 
 Drug-induced liver disease was classified according to Benichou (26) 
and the severity of liver disease according to Donelli et al. (27) (see  
Table 6.2). 
 
6.4 Results 
 Informations about all antineoplastic drugs on the market in Switzerland by the 
end of the year 2003 were collected. Using our search strategy, we identified a total 
of 112 articles which were found to be relevant for our study. In 64 of them, kinetic 
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data were reported and 48 contained hepatic adverse effects of antineoplastic a-
gents. 
 
Table 6.1 Categorization of antineoplastic drugs screened according to pharmacoki-
netic variables. 
 
High hepatic extraction (category 1) 
• Hepatic extraction > 60% → oral bioavailability < 40% in the case of complete 
intestinal absorption (or accordingly lower, if intestinal absorption is not complete) 
 
Intermediate hepatic extraction (category 2) 
• Hepatic extraction 30 - 60% → oral bioavailability 40 - 70% in the case of 
complete intestinal absorption (or accordingly lower, if intestinal absorption is not 
complete) 
 
Low hepatic extraction (category 3) 
• Hepatic extraction < 30% → oral bioavailability > 70% in the case of complete 
intestinal absorption (or accordingly lower, if intestinal absorption is not complete) 
• In this category, protein binding may be relevant: for drugs with high binding to 
albumin (>90%), hepatic clearance may increase 
 
Hepatic extraction is not known (category 4) 
 
 The 69 antineoplastic drugs on the Swiss market by the end of the year 2004 are 
listed in Table 6.3. From these 69 drugs, 10 fell into category 1, 11 into category 2 
and 28 in category 3. Twenty drugs could not be classified (category 4), demonstra-
ting a lack of data about hepatic extraction and/or bioavailability. 
 Fifty-two out of the 69 drugs had a Q0 value (extrarenal dose fraction, compare 
Table 6.3) >0.4, indicating that most antineoplastic drugs are heavily metabolized 
and/or excreted by the bile. Seven drugs had a Q0 value ≤0.4 and for 10 drugs, the 
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Q0 value could not be identified. For 25 drugs, metabolism by the cytochrome P450 
system (CYP) is important, and 18 drugs are excreted to a significant extent (> 5%) 
 
Table 6.2 Classification of liver disease and severity of liver dysfunction 
 
Parameter Pathophysiological condition 
and clinical significance 
Severity1 
Alanine amino-
transferase (ALT) 
Breakdown (necrosis or apop-
tosis) of hepatocytes. 
Hepatocellular injury2 if > 2 x 
ULN3  
2-5 x ULN: moderate injury 
> 5 x ULN: severe injury 
Alkaline phospha-
tase 
Cholestasis4 if > 2 x ULN 
 
2-5 x ULN: moderate cholestasis 
> 5 x ULN: severe cholestasis 
Serum bilirubin 
concentration 
Cholestasis (exclude  
prehepatic causes)  
25 – 50 µmol/L: moderate 
> 50 µmol/L: severe 
Serum albumin 
concentration 
Impaired hepatic protein  
synthesis  
30 – 35 g/L: moderate 
< 30 g/L: severe 
Prothrombin  
activity 
Impaired hepatic protein  
synthesis  
40 – 70%: moderate 
< 40%: severe 
 
1The severity is classified according to Donelli et al. (27) with some modifications 
2Hepatocellular injury is defined according to Benichou (26) 
3ULN: upper limit of normal 
4Cholestasis is defined according to Benichou (26) 
 
by the bile (vinca alkaloids, doxorubicin and derivatives, amsacrine, biculatamide, 
dactinomycin, estramustine, exemestan, irinotecan, imitanib, mitoxantrone, paclitaxel 
and topotecan). For 13 of these drugs, dose adaptation recommendations are given 
according to the serum bilirubin concentration and/or activity of alkaline phosphatase. 
For biculatamide, estramustine, exemestan and paclitaxel, there is a general state-
ment that the dose should be adapted or stopped in patients with decreased liver 
function. For topotecan, no dose reduction is recommended in patients with liver di-
sease. For 16 of the 64 drugs studied, recommendations for dose adaptation are ba-
sed studies in patients with hepatic dysfunction. 
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 For 42 of the drugs, significant adverse effects on the liver have been reported. 
This is important to realize, rendering drug-induced liver disease an important diffe-
rential diagnosis in patients with malignant tumors and impaired hepatic function. 
 
6.5 Discussion 
 Our study demonstrates that for antineoplastic drugs, there is a discrepancy bet-
ween the general recommendations of how drugs should be dosed in patients with 
liver disease and the available kinetic data for these drugs. The most important gaps 
are a lack of information regarding hepatic extraction and of kinetic studies for critical 
drugs in patients with impaired liver function. 
 As explained in the introduction, data about hepatic extraction are important for 
classification of a specific drug regarding hepatic elimination in patients with chronic 
liver disease, in particular liver cirrhosis. It is evident that such data are difficult to ob-
tain, especially the determination of hepatic extraction of a drug, necessitating an in-
vasive procedure which is usually not performed before a drug is marketed. Bioavai-
lability is only a surrogate for hepatic extraction, since a low bioavailability can be ex-
plained by both a high hepatic extraction and/or a low intestinal absorption. For drugs 
with a low bioavailability (<40%), hepatic extraction should therefore be known, since, 
as explained above, this parameter is critical for rational drug dosing in patients with 
impaired liver function. In order to circumvent this invasive procedure in humans, a 
possibility would be to get such data using perfused livers from animals, e.g. pigs. To 
the best of our knowledge, no data have been published so far comparing hepatic 
extraction data for critical drugs between animals (such as pigs) and humans. A-
nother possibility is to estimate hepatic extraction using the extrarenal fraction (Q0), 
systemic drug clearance and hepatic blood flow (equation 4 and Table 6.3). As 
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shown in Table 6.3, the values obtained with this technique are in a satisfactory 
agreement with the bioavailability for most drugs, with some exceptions. 
 Regarding antineoplastic agents, many of these drugs are used intravenously on-
ly, partially explaining the lack of data considering oral bioavailability. Nonetheless, 
taking into account the high prevalence of patients with impaired hepatic function 
among those treated with this type of drugs (28), such data should be available for all 
substances on the market. 
 Kinetic studies have been conducted in particular in two conditions, namely pati-
ents with cholestasis (as suggested by an increased serum bilirubin concentration) 
and in patients with hepatic metastases. Considering cholestasis, studies exist for 
most antineoplastic drugs with significant biliary elimination (see Table 6.3). These 
studies resulted in quantitative recommendations for dose adaptation in jaundiced 
patients according to their serum bilirubin concentration. To the best of our knowled-
ge, however, these recommendations have not been validated by kinetic and dyna-
mic studies (including the incidence and severity of dose-dependent adverse effects) 
in a large series of patients with cholestasis. It remains also unclear, whether the se-
rum bilirubin concentration is the best parameter for dose adaptation in cholestatic 
patients or whether, for instance, the serum bile acid concentration and/or activity of 
alkaline phosphatase would be more suitable. 
 Considering hepatic metastases, only few studies exist and they have generally 
not resulted in clear dose adaptation recommendations. Since hepatic metastases 
can be associated with portal hypertension and possibly porto-caval shunts (10, 18), 
the situation resembles patients with liver cirrhosis. Oral administration of drugs with 
a high hepatic extraction should therefore be performed cautiously and kinetic data 
for such drugs should be available in this type of patients when such drugs are ap-
proved. 
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 As shown in Table 6.3, treatment with antineoplastic agents can lead itself to liver 
disease or, for drugs metabolized by the liver and/or excreted by the bile, to increa-
sed systemic toxicity in patients with liver disease. There is a third type of toxicity 
which may be relevant. In several patients with chronic hepatitis B, the immuno-
suppressive effect of antineoplastic agents was associated with a flare up of their he-
patitis due to increased replication of the hepatitis B virus (29-35). Since this conditi-
on can be treated but is potentially fatal (35), the immune status regarding hepatitis B 
should be known before treatment with antineoplastic drugs. 
 In conclusion, there are currently considerable gaps in the data needed for safe 
administration of antineoplastic drugs in patients with decreased hepatic function. 
Drug authorities should urge pharmaceutical companies to provide such data before 
the drugs are approved. Considering kinetics, in particular oral bioavailability and he-
patic extraction should be investigated. For drugs with a predominant hepatic meta-
bolism and/or excretion, the kinetics in patients with liver metastases and/or cho-
lestasis should have been studied before marketing authorisation is provided. 
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Table 6.3 Kinetic data, hepatic adverse effects and dose recommendations in patients with liver disease of the antineoplastic drugs on 
the market in Switzerland by the end of the year 2004 
 
Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
Aldes-
leukin 
4 Not known 0.18 
 
1 - -   Frequent: hepa-
tocellular injury, 
cholestasis, or 
hyperbili-
rubinemia (20). 
Recommendation: Monitor patients for ad-
verse effects, dose may need to be adjusted 
patients with liver disease (20, 22). Contrain-
dicated in patients with elevated serum bili-
rubin (20). 
Alemtu-
zumab 
4 Not known 0.15 
 
8 - -    No dose adjustment recommendations avai-
lable for patients with liver disease 
Amino-
glutethi-
mide 
3 0.50 
N-acetylation, 
N-hydroxylation 
(CYP) (22) 
1.00 
 
12 25 95 4.5 0.03 Sporadic: cho-
lestasis, hyperbi-
lirubinemia (23). 
No dose adjustment recommendations avai-
lable for patients with liver disease. 
Amsacri-
ne 
 
4 1 
Glutathion con-
jugation, Biliary 
excretion (20) 
1.40 5 97 -   Sporadic: cho-
lestasis, hyperbi-
lirubinemia (23). 
Recommendation: 50% dose reduction if se-
rum bilirubin > 34 µmol/l (36). Dose reduction 
(70% of normal dose) in patients with severe 
liver disease (20, 22). 
Anastro-
zole 
 
4 0.95 
N-dealkylation, 
hydroxylation 
(CYP), glucu-
ronidation (22) 
- 50 45 80   Sporadic: cho-
lestasis. 
No dose adjustment recommendations avai-
lable for patients with liver disease. 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
Bicaluta-
mide 
 
2 ≈1 
Oxidation 
(CYP), glucu-
ronidation. Bili-
ary elimination 
40% (20) 
- 139 
 
98 - 30 0.34 
 
One case of ful-
minant liver failu-
re (37) 
Recommendation: Stop treatment if transa-
minases > 3 x ULN or in patients with hyper-
bilirubinemia (20) 
Bleo-
mycin 
 
3 0.70 
Hydrolysis (22) 
0.30 3 - - 5.2 0.04 Case reports: 
steatosis (23, 38) 
Recommendation: No dose adjustment in 
patients with liver disease (22). 
Buserelin 
 
3 Not known 
 
- 1.6 - 3    No dose adjustment recommendations avai-
lable for patients with liver disease. 
Busulfan 
 
3 1 
Oxidation, sul-
fation 
1.0 2.5 30 70 18.9 0.21 Sporadic: hepa-
tocellular injury, 
cholestasis (39, 
40). 
Rare: venoocc-
lusive disease 
(23). 
No dose adjustment recommendations avai-
lable for patients with liver disease. 
Capeci-
tabine 
1 0.97 
Carboxyleste-
rase, Cytidine 
desaminase, 
phosphorylation 
- 1.3 54 42 251 >1 Frequent: hyper-
bilirubinemia 
Sporadic: cho-
lestasis 
Rare: Hepatocel-
lular injury (41) 
Studies: Increased bioavailability by 20% in 
patients with moderate liver disease due to 
metastases (42). 
Recommendation: No dose adjustment in 
patients with moderate liver disease (42) 
Carbo-
platin 
3 0.25 0.24 3 20 - 4.5 0.01 Rare: hepatocel-
lular injury, cho-
lestasis (23) 
Recommendation: No dose adjustment in 
patients with liver disease (20) 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
Cetuxi-
mab 
4 Binding to 
EGFR in hepa-
tocytes and 
skin (43) 
0.05 120 - - 0.03  Frequent: 
mild elevations 
of transaminases 
and alkaline 
phosphatase 
(44) 
No dose adjustment recommendations avai-
lable for patients with liver disease 
Chloram-
bucil 
3 1 
β-oxidation (22) 
1.0 1.5 99 87 11 0.12 Rare: hepatocel-
lular injury (23) 
Case report: liver 
failure (45).  
Recommendation: Monitor patients for ad-
verse effects, dose may need to be adjusted 
patients with liver disease (20) 
Chlorme-
thine 
(Mechlor-
thamine) 
4 1 
ethyleneimmo-
nium ion (22) 
- - - -    No dose adjustment recommendations avai-
lable for patients with liver disease. 
Cisplatin 3 0.65 
non-enzymatic 
degradation 
(46) 
0.3-1 0.5 90 - 0.3 0.01 Rare: hepatocel-
lular injury (23) 
Recommendation: No dose adjustment in 
patients with liver disease (20, 22) 
Cladri-
bine 
2 Not known 0.4 6 25 55 60   No dose adjustment recommendations avai-
lable for patients with liver disease. 
Cyclo-
phos-
phamide 
3 0.9 
Hydroxylation 
by CYPs 2B6, 
2C19, 2C9, 
3A4 (47) 
0.80 7 15 75 4.4 0.04 Rare: Hepatocel-
lular injury, cho-
lestasis, hyperbi-
lirubinemia (23). 
Case reports: 
venoocclusive 
disease (48-50) 
Studies: Decreased clearance of active drug 
and decreased production of active metaboli-
tes in patients with liver metastases (51), se-
vere liver disease in the presence of Hodg-
kin’s disease (52) or liver cirrhosis (36).  
Recommendation: Monitor patients with liver 
disease for adverse effects. Dose reduction 
by 25% in patients with serum bilirubin > 50 
µmol/L (20) 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
Cyprote-
rone 
3 1 
hydrolysis, hy-
droxylation, 
conjugation 
(22) 
19 38 95 88   Sporadic: hepa-
tocellular injury, 
cholestasis, hy-
perbilirubinemia 
Rare: liver failure 
(53-57) 
Recommendation: Monitor liver function. 
Stop treatment in patients with liver injury 
(20, 22) 
Cytarabi-
ne 
2 0.90 
cytidine deami-
nase (22) 
3.0 2.3 13 <20 55 0.55 Sporadic to fre-
quent: dose-
dependent hepa-
tocellular injury, 
cholestasis, hy-
perbilirubinemia 
(23) 
Recommendation: 50% dose reduction if se-
rum bilirubin > 34 µmol/L, gradual increase 
while monitoring systemic toxicity (36) 
Dacarba-
zine 
3 0.30 1.5 0.7 5 - 12 0.04 Case reports: 
venoocclusive 
disease (58, 59), 
hepatic vein 
thrombosis (59) 
No dose adjustment recommendations avai-
lable for patients with liver disease. 
Dactino-
mycin 
4 0.70 
Biliary excretion 
50%-90% (22) 
12 36 - -   Rare: hepatocel-
lular injury, stea-
tosis, venoocclu-
sive disease (23) 
Recommendation: 50% dose reduction in pa-
tients with hyperbilirubinemia. Increase gra-
dually while monitoring systemic toxicity (36). 
Dauno-
rubicin 
4 0.90 
Reduction, bili-
ary excretion 
40% (22) 
40 27 - -   Rare: Venoocc-
lusive disease 
when combined 
with radiation 
(23) 
Recommendation: If serum bilirubin 20 - 50 
µmol/L 25% dose reduction, if serum bilirubin 
> 50 µmol/L 50% dose reduction (20, 22) 
Doceta-
xel 
2 1 
Oxidation by 
1.6 0.6 
(β) 
95 - 39 0.43  Studies: Population kinetic studies show a 
25% reduction of clearance in patients with 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
CYP3A4 (22). 
Biliary excretion 
75%, 10% as 
intact drug (20, 
22) 
11 
(γ) 
transaminases > 1.5 x ULN and alkaline 
phosphatase > 2.5. In patients with moderate 
liver injury/cholestasis clearance was redu-
ced by 27% (20, 22). 
Recommendation: If transaminases > 1.5 x 
ULN or alkaline phosphatase > 2.5 x ULN 
25% dose reduction. If serum bilirubin is inc-
reased or transaminases > 3.5 x ULN or al-
kaline phosphatase > 6 x ULN docetaxel 
should not be adminstered (20, 22) 
Doxo-
rubicin 
1 0.95 
Reduction to 
doxorubicinol, 
sulfation, glucu-
ronidation, biliar 
excretion 50% 
(22, 27) 
17 26 80 5 69 0.73 Rare: in combi-
nation with cyc-
lophosphamide, 
etoposide and 
cisplatin cho-
lestasis and ve-
noocclusive di-
sease (23) 
Studies: In 5 patients with disseminated sar-
coma, bone marrow toxicity and doxorubicin 
serum levels correlated with hyperbilirubine-
mia (60). In patients with hepatocellular car-
cinoma, bone marrow toxicity and serum do-
xorubicin/doxorubicinol levels correlated with 
hyperbilirubinemia (61, 62). In 17 patients 
with liver metastases and moderate liver di-
sease kinetics of doxorubicin was not chan-
ged but the half-life of doxorubicinol increa-
sed (63). In 4 patients with moderate liver 
disease the half-life of doxorubicin was 
doubled (64). In patients with liver metasta-
ses and mild increase in transaminases or 
alkaline phosphatase, kinetics and toxicity of 
doxorubicin was not changed (61, 62, 65, 
66). 
Recommendation: If serum bilirubin 20 - 50 
µmol/l: 50% dose reduction. If serum bilirubin 
> 50 µmol/l: 75% dose reduction (20, 22, 36, 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
67). Donelli et al. advise dose reduction only 
if serum bilirubin is > 50 µmol/L (27). 
Epirubicin 1 0.90 
Reduction 
Biliar excretion 
40% (68) 
20 39 85 - 89 0.89  
 
Studies: In patients with liver metastases and 
increased serum bilirubin, the half-life of epi-
rubicin/epirubicinol was increased (69-71). In 
patients with hepatocellular carcinoma, epi-
rubicin kinetics correlates with liver function 
and serum bilirubin (72). In patients with liver 
metastases, epirubicin kinetics correlates 
better with transaminases than with serum 
bilirubin (73-75). 
Recommendation: If serum bilirubin 20 - 50 
µmol/l: 50% dose reduction. If serum bilirubin 
> 50 µmol/l: 75% dose reduction (20, 22, 36) 
Estra-
mustine 
2 0.90 
Oxidation, par-
tial biliary exc-
retion (76) 
0.04 1.3 99 44   Sporadic. Hepa-
tocellular injury, 
cholestasis (20) 
Recommendation: Monitor patients for ad-
verse effects, dose may need to be adjusted 
patients with liver disease (20). 
Etoposi-
de 
3 0.65 
Esterases, glu-
curonidation. 
Biliary excretion 
<10%. 
0.30 8.1 95 50 2.9 0.02 Frequent. Hepa-
tocellular injury 
(23).  
Case reports: 
Reactivation of 
hepatitis B virus 
(30), liver failure 
(77) 
Studies: In patients with mild to moderate li-
ver disease, etoposide kinetics was not alte-
red (78-80). In patients with severe liver di-
sease elimination and AUC were highly vari-
able and tended to be increased in the case 
or impaired hepatic protein synthesis or hy-
perbilirubinemia (78-81). 
Recommendation: Monitor patients with mild 
to moderate liver disease. If bilirubin 25 – 50 
µmol/L or AST > 180 U/L 50% dose reducti-
on (36). Contraindicated in patients with de-
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
compensated liver disease (20, 22). 
Exe-
mestane 
1 1 
CYP3A, biliary 
excretion 40% 
(82) 
19 24 90 42 609 >1 Sporadic hepa-
tocellular injury, 
cholestasis (20) 
Recommendation: Monitor patients for ad-
verse effects, dose may need to be adjusted 
patients with liver disease (20). 
Fludara-
bine 
3 0.35 
 
2.4 10-
30 
- 70 15.5 0.06  Recommendation: No dose adjustment re-
commended in patients with liver disease 
(20, 22). 
Fluoro-
uracil 
1 0.95 
Dihydropyrimi-
dine dihydro-
genase 
0.3 0.25 94 28 67.2 0.71 Sporadic: hepa-
tocellular injury 
when administe-
red i.v. (23) 
Studies: In patients with liver metastases, a 
weak correlation with cholestasis was pre-
sent (83), but no dose adjustment was re-
commended. 
Recommendation: Start with 50% of normal 
dose in patients with liver cirrhosis. Increase 
gradually while monitoring systemic toxicity 
(27, 36). 
Flutamide 4 1 
Hydroxylation 
(84) 
- 8 95 -   Sporadic: hepa-
tocellular injury, 
hyperbilirubine-
mia (20). 
Case reports: 
liver failure (85-
92). 
Recommendation: Monitor liver function (20). 
For-
mestane 
1 Not known - 120 93 25    No dose adjustment recommendations avai-
lable for patients with liver disease  
Fosfestrol 3 1 - 0.5 - 80    Recommendation: Monitor liver function (20, 
22).  
Gefitinib 2 
 
CYP3A4, 
CYP2D6 (93) 
20 27 90 50   Frequent: 
hepatocellular 
No dose adjustment recommendations avai-
lable for patients with liver disease 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
 
 
 
 
injury, cholesta-
sis (21) 
Recommendation: Reduce dosage by 50% 
or avoid in patients with liver disease (93) 
Gemcita-
bine 
1 0.9 
Deamination, 
phosphorylation 
(20) 
25 1 – 
12 
10 - 90 0.9 Frequent: hepa-
tocellular injury 
(self-limiting) (20, 
22) 
No dose adjustment recommendations avai-
lable for patients with liver disease 
Goserelin 3 0.4 - 4.0 25 - 8.2 0.04  Recommendation: Dose adjustment not re-
commended in patients with liver disease 
(20). 
Hydroxy-
carbami-
de 
3 0.4 0.5 5.0 80 80   Case report: ful-
minant liver failu-
re (94) 
No dose adjustment recommendations avai-
lable for patients with liver disease 
Idarubicin 1 ≈1 
Oxidation, bilia-
ry excretion 8 – 
17% (95, 96) 
- 15.2 96 28 120 ≈1 Frequent: hepa-
tocellular injury, 
hyperbilirubine-
mia (20) 
Studies: In patients with metastases, kinetics 
of idarubicin is not changed (97, 98). 
Recommendation: If serum bilirubin 20 - 34 
µmol/l: 50% dose reduction. If serum bilirubin 
> 34 µmol/l: contraindicated (20) 
Ifosfami-
de 
3 0.5 
CYP3A (activa-
tion) (47) 
0.5 6.5 - 100 3.6 0.02 Sporadic: hepa-
tocellular injury, 
hyperbilirubine-
mia (23) 
Recommendation: Monitor patients with pre-
existing liver disease (20). Contraindicated in 
patients with decompensated liver disease 
(22). 
Imatinib 3 0.95 
N-
demethylation 
(CYP 3A), 20% 
biliary elimina-
tion (20) 
4.9 18 95 98   Sporadic: hyper-
bilirubinemia, 
hepatocellular 
injury (20). 
Recommendation: Stop treatment if serum 
bilirubin > 3 x ULN or transaminases > 5 x 
ULN (20) 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
Irinotecan 3 0.75 
Esterases, glu-
curonidation, 
CYP3A4  
Biliary excretion 
25% (20, 99) 
75 10 65 - 26 0.21  Study: In patients with gastrointestinal cancer 
and cholestasis the AUC for SN-38 (active 
metabolite) was 50% increased (serum bili-
rubin 1.1-1.5 x ULN) or 100% increased 
(>1.5 ULN) (100). 
Recommendation: If serum bilirubin > 1.5 x 
ULN/transaminases > 5 x ULN dose reducti-
on according to adverse events. Contraindi-
cated if serum bilirubin > 5 x ULN (20). Ac-
cording to (100) 350 mg/2 in patients with se-
rum bilirubin 1.1-1.5 ULN and 200 mg/m2 
when serum bilirubin >1.5 ULN. 
Letrozol 3 0.95 
CYP3A4, 2D6 
(20) 
1.9 45 60 100 2.4 0.03  No dose adjustment recommendations for 
patients with liver disease available 
Leuprore-
lin 
3 Not known 0.5 3 46 - 8.3 0.05  No dose adjustment recommendations avai-
lable for patients with liver disease 
Lomu-
stine 
3 1 
Cis- and trans-
4-hxdroxylation 
(101) 
1.70 10 - ≈100   Sporadic: hepa-
tocellular injury 
(20) 
No dose adjustment recommendations avai-
lable for patients with liver disease 
Medroxy-
progeste-
ron 
1 1 
CYP3A4  
0.6 36 94 <10 76 0.84 Rare: cholesta-
sis, peliosis (20) 
No dose adjustment recommendations avai-
lable for patients with liver disease. 
Megestrol 4 1 
Glucuronidation 
(22) 
- 18 - -   Rare: hepatocel-
lular injury, hy-
perbilirubinemia 
(20) 
No dose adjustment recommendations avai-
lable for patients with liver disease 
Melpha- 2 0.9 0.6 1.5 80 70 31 0.31  Recommendation: No adjustment recom-
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
lan Hydroxylation 
(22) 
mended in patients with liver disease (22). 
Mercap-
topurine 
2 0.9 
Xanthine oxi-
dase (thiouric 
acid), thiopuri-
ne methyltrans-
ferase (22) 
0.6 0.9 19 12 46 0.46 Frequent: dose-
dependent hepa-
tocellular injury, 
cholestasis, hy-
perbilirubinemia 
in 6 – 40% (23). 
Case reports: 
liver failure (102-
105), venoocclu-
sive disease 
(23). 
Risk may be hig-
her in patients 
with reduced ac-
tivity of thiopuri-
ne methyltrans-
ferase 
Recommendation: Monitor liver function. 
Contraindicated in patients with decompen-
sated liver disease (20) 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
Metho-
trexate 
3 0.05 0.70 7.2 50 70 8.8 0.01 Sporadic: Fatty 
liver, fibrosis, cir-
rhosis during 
long-term treat-
ment with immu-
nosuppressive 
doses (106-112). 
Case reports: 
hepatocellular 
injury, acute liver 
failure during use 
as an antine-
oplastic agent 
(30, 113-116) 
 
Studies: No correlation between liver function 
and methotrexate serum levels (117). 
Recommendation: Close monitoring in pati-
ents with decompensated liver disease. Re-
duce dose in the presence of ascites and/or 
decreased renal function (20, 22) 
Mitomy-
cine 
 
4 0.9 0.3 0.5 - -   Rare: steatosis  
Case reports: 
venoocclusive 
disease (23) 
No dose adjustment recommendations avai-
lable for patients with liver disease 
Mito-
xantrone 
2 0.95 
mono- or dicar-
boxylation (i-
nactive), biliary 
excretion 25% 
(20) 
10 - 
15 
57 76  - 45 0.48 Frequent: hepa-
tocellular injury 
(23) 
Studies: Clearance reduced by 50% in pati-
ents with moderate liver disease (118). 
Patients with serum bilirubin < 60 µmol/L to-
lerate 14 mg/m2, patients with serum bilirubin 
> 60 µmol/L and bad performance status ha-
ve higher mortality with this dosage (119). In 
patients with liver metastases, half-life of mi-
toxantrone correlated with serum bilirubin 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
and cholestasis (120). 
Recommendation: Dose adjustment (8 
mg/m2) or contraindicated (bad performance 
status) in patients with serum bilirubin > 60 
µmol/L (119) 
Nimusti-
ne 
4 1 - 0.6 34 -    No dose adjustment recommendations avai-
lable for patients with liver disease  
Oxali-
platin 
4 ≈0.5, 
Reduction 
(non-
enzymatic), bi-
liary excretion 
5% (121) 
- 260 75 -    Recommendation: No dose adjustment in 
patients with liver disease (20). 
Paclitaxel 3 0.95 
CYP 3A, 2C8. 
Biliary excretion 
> 5% (122) 
2.0 3 95  23 0.24 Sporadic: hepa-
tocellular injury, 
cholestasis 
Rare: hyperbili-
rubinemia, liver 
failure (20) 
Studies: Liver disease/liver cirrhosis appears 
to be a risk factor liver for systemic toxicity 
(123, 124). Increased risk for myelosuppres-
sion in patients with increased transamina-
ses and/or serum bilirubin > 25 µmol/L (125). 
In patients with increased transaminases (3-
10 x ULN) and hyperbilirubinemia (1.3 – 2 x 
ULN) clearance was decreased by ≈ 40% 
(126) 
Recommendation: Monitor patients with liver 
disease well for adverse effects. Do not ad-
minister in patients with decompensated liver 
disease (20, 126) 
Ralti-
trexed 
4 0.5 
Polyglutamate 
derivative (127) 
7.0 2 93 -   Frequent: hepa-
tocellular injury 
Sporadic: cho-
Recommendation. No dose adjustment in 
patients with mild to moderate liver disease. 
Contraindicated in patients with decompen-
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
lestasis, hyperbi-
lirubinemia 
Case report: liver 
failure (128) 
sated liver disease (20). 
Rituxi-
mab 
4 Not known - 68 - -    No dose adjustment recommendations avai-
lable for patients with liver disease 
Tamoxi-
fen 
4 1 
Hydroxylation, 
N-dealkylation 
(CYP 2C9, 
2D6, 3A4, 2C8) 
(22) 
60 4 – 
11 
days 
99 -   Sporadic: hepa-
tocellular injury, 
cholestasis, fatty 
liver (23). 
Rare: liver failure 
(129-131). 
Studies: In a patient with liver metastases 
liver function deteriorated one year after start 
of tamoxifen (132). In a randomized trial in 
patients with hepatocellular carcinoma, liver 
function was not affected (133). 
Recommendation: Monitor liver function in 
patients with preexisting liver disease. 
Temozo-
lomide 
3 0.9 
non-enzymatic 
- 1.8 15 ≈100    No dose adjustment recommendations avai-
lable for patients with liver disease 
Thiotepa 3 0.5 
CYP 2B1, 2C11 
(134) 
- 2.4 99 - 19 0.11 Case report: liver 
failure (135) 
No dose adjustment recommendations avai-
lable for patients with liver disease 
Tioguani-
ne 
4 >0.9, 
Thiopurine me-
thyltransferase 
- 5 - 9 - -   Rare: hepatocel-
lular injury, cho-
lestasis (23). 
Case reports: 
Veno-occlusive 
disease (136, 
137) 
Recommendation: Monitor liver function after 
administration of high doses. Contraindicated 
in patients with decompensated liver disease 
(20). 
Topote-
can 
2 0.6 
Esterases 
Biliar excretion 
20% (138) 
1.9 2.4 35 32 49.5 0.33  Studies: 14 patients with increased transa-
minases and/or hyperbilirubinemia (some 
with cirrhosis) were treated with 1.5 mg/m2. 
Topotecan clearance correlated with ICG 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
clearance but no more adverse effects were 
observed in patients with liver disease (139). 
On the other hand, two thirds of patients with 
hepatocellular carcinoma treated with topo-
tecan developed grade IV neutropenia (140). 
Recommendation: No dose adjustment for 
patients with hepatic dysfunction but monitor 
patients well for systemic toxicity (139). 
Toremi-
fen 
3 1, 
CYP3A4 (N-
demethylation, 
hydroxylation). 
Enterohepatic 
circulation 
(141) 
12-15 148 99 ≈100 4.5 0.05  
 
 
 
Studies: In 10 patients with liver cirrhosis or 
fibrosis the elimination half-life was increased 
by 75% and clearance decreased by 28% 
(141). 
Recommendation: Dose reduction in patients 
with liver cirrhosis by 50%, gradual increase 
while monitoring adverse effects (20). 
Trastuzu- 
mab 
4 Not known 0.04 140 - -    No dose adjustment recommendations avai-
lable for patients with liver disease  
Tretinoin 
 
4 CYP2C8, I-
sotretinoin, 4-
oxo-retinoic a-
cid (21) 
- 1.25 95 -   Frequent: 
hepatocellular 
injury (93) 
Recommendation: Need for dosage ad-
justments in patients with hepatic impairment 
has not been shown. A dose reduction to 25 
mg/m2 is recommended as a precautionary 
measure (21). 
Tripto-
relin 
3 
 
0.52 0.5 3 - - 5 0.03  Studies: As compared to 6 healthy young 
males, 6 patients with normal renal function 
and hepatic impairment (Child A or B) had 
decreased total clearance (57 versus 210 
mL/min) and prolonged elimination half-life 
(7.6 versus 2.8 hours) after a single intrave-
nous bolus of 0.5 mg triptorelin. Despite the-
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
se differences after intravenous dosing, dose 
reduction of the sustained-release formulati-
on used clinically is judged not necessary, 
because its release rate is much slower than 
its elimination rate (142). 
Recommendation: Dosage reduction of sus-
tained-release triptorelin does not appear to 
be necessary in patients with liver disease 
(142). 
Vinblasti-
ne 
2 1 
CYP3A4 
biliary excretion 
>50% (22) 
20 25 75 - 52 0.58  Recommendation: If serum bilirubin > 50 
µmol/L → 50% dose reduction (20). 
Vin-
cristine 
3 0.9 
CYP3A4 
biliary excretion 
70% (22) 
8.0 23 75 - 8.5 0.09  Studies: In the presence of cholesta-
sis/hyperbilirubinemia β-half-life was prolon-
ged (144). In patients with leukemia or 
lymphoma and cholestasis, AUC and toxicity 
were increased (145). 
Recommendation: If serum bilirubin > 50 
µmol/L → 50% dose reduction (20). Some 
authors advise 50% dose reduction also if 
alkaline phosphatase is increased (36). 
Vindesine 4 Not known 
CYP 3A, biliar 
excretion 
8.8 24 - - 17.5   Recommendation: Monitor patients for ad-
verse effects, dose may need to be adjusted 
patients with hyperbilirubinemia (20). 
Vin-
orelbine 
1 0.85 
CYP 3A, biliary 
excretion 50% 
(22, 146) 
75 30 15 ≈40    Studies: In 19 patients with liver metastases, 
clearance was reduced by 50% in patients 
with >75% of the liver replaced by tumor 
(147). 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Studies performed and dosage recom-
mendations 
  Q02, metabo-
lism 
Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(L/h) 
E8   
Recommendation: 50% dose reduction if mo-
re than 75% of liver replaced by tumor (147) 
or if serum bilirubin > 34 µmol/L (146). 
 
1Cat = drug category. Drugs were categorized as follows: Category 1: high hepatic extraction (E) (E > 60%, bioavailability < 40%), ca-
tegory 2: intermediate hepatic extraction (E = 30-60%, bioavailability 40-70%), category 3: low hepatic extraction (E < 30%, bioavaila-
bility >70%), category 4: hepatic extraction not known 
2Q0: extrarenal dose fraction = fraction metabolized or excreted by bile (1 - Q0: fraction excreted unchanged by the kidney) 
3Vd = volume of distribution in L per kg. For calculation, body weight was assumed to be 70 kg. 
4 t½: dominant half-life 
5PB: Fraction bound to proteins (protein binding in %) 
6F: Bioavailability 
7Clsys: systemic clearance (L/min) 
8E: hepatic extraction, calculated as described in equation 4 
9Frequency of hepatic adverse effects: frequent > 10% of patients treated, sporadic: 1-10%, rare: < 1% 
Abbreviations: CYP = cytochrome P450, ULN = upper limit of normal 
Characterization of liver disease and severity of liver dysfunction: compare Table 2 
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7 Discussion and Conclusions 
The dissertation shows that drug safety in hospitals can be improved on different le-
vels: Considering medication errors, we could show that the prevalence of drug-drug inte-
ractions is high in ambulatory patients, a finding which has been reported also in hospitali-
zed patients on medical wards (1). In addition, considering dose adaptation in patients with 
liver disease, we could show that even for such important drugs as antineoplastic agents, 
much information is lacking. 
 So far, it is unclear, however, how strong such risk factors are, or in other words, 
how many patients affected by such risk factors will finally develop an adverse drug reacti-
on. Some information has been published on the risk of patients with potential drug-drug 
interactions. In patients treated with the combination of an ACE-inhibitor or an angiotensin 
receptor blocker and low dose (25 mg/day) spironolactone, the incidence of severe hyper-
kalemia (>6 mmol/L) is in the range of 6% per year (2). It has also been shown that the risk 
to develop hypoglycemia in patients treated with a sulfonylurea is increased by a factor of 
6 in the presence of concomitant treatment with co-trimoxazole (3). In the same study, the 
risk for severe digoxin toxicity was increased by a factor of approximately 20 in patients 
treated concomitantly with clarithromycin (3). The absolute risk was not given in these stu-
dies, but can be expected to be quite high (affecting more than 1% of the patients treated 
per year), since the incidence of hypoglycemia in patients treated with oral antidiabetics or 
of digoxin toxicity is in this range. In contrast, although concomitant treatment of patients 
ingesting atorvastatin or simvastatin with a CYP3A4-inhibitor increases the relative risk by 
a factor in the range of 10 (4), the absolute risk is still low (in the range of 1:1000 to 
1:10’000 patient years), since the incidence of rhabdomyolysis in patients treated with sta-
tins is low. The examples show that that the frequency of adverse drug reactions due to 
drug-drug interactions depends not only on the type of interaction, but also on the adverse 
drug reaction itself. In comparison, the literature contains no data about the risk for adver-
  
 
135
se drug reactions in patients with liver disease treated with drugs which should be reduced 
at a reduced dosage in this situation. In order to find out the benefit of dose adaptation in 
patients with liver disease, such studies would be necessary. 
 Regarding adverse drug reactions, it is interesting to make a comparison between 
the incidence reported by Lazarou et al. (5) and the one found in our study. The mean gi-
ven by Lazarou et al. (6.7% of patients per hospitalization) and the median found by us 
(6% of the patients) are almost identical. Since Lazarou et al. included studies between 
1966 and 1996 and most studies included by us were published after 1996, the compari-
son suggests that the incidence of adverse drug reactions in hospitalized patients did not 
change much over the last 40 years, despite many new drugs on the market. Newer drugs 
seem therefore not to be associated with fewer adverse effects under hospital conditions. 
Such conclusions have to be drawn with caution however, since we did not systematically 
assess the severity of the adverse drug reactions and also regarding the high variability of 
the frequencies of adverse drug reactions among studies. 
 The studies open a large field of occupation for clinical pharmacists. Several studies 
could show that clinical pharmacists on the ward can help to reduce medication errors (6-
10). Taking into account the cost of adverse drug reactions or adverse drug events (11-14) 
and assuming that most adverse drug reactions/events are avoidable (15-21), the occupa-
tion of clinical pharmacists on the wards could be cost beneficial. While clinical pharma-
cists have a long tradition in English speaking countries such as Great Britain and the Uni-
ted States of America, this is not the case in Switzerland. In particular in smaller hospitals 
(cantonal, regional and district hospitals), hospital pharmacists have to play the role of cli-
nical pharmacists (due to lack of finances to engage a clinical pharmacist). It is therefore 
essential that hospital pharmacists have a good training in clinical pharmacy during their 
formation. This would mean that larger hospitals (in particular University Hospitals) should 
build up clinical pharmacy units, which would not only have to organize the practical work 
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on the wards and research projects, but would also have to care for the formation of hospi-
tal pharmacists in clinical pharmacy. The future will show, whether this will happen in  
Switzerland, since budget constraints are also operative in University Hospitals. My work 
demonstrates that there are enough studies in the literature providing evidence that this 
would be a good strategy to improve hospital drug safety. 
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